In de nieuwe podcast Kick-off reageert chef voetbal Valentijn Driessen uitgebreid op zijn Sébastien Haller-uitspraak, dat de spits niet goed genoeg zou zijn voor de Champions League. Vervolgens maakte Haller er vier tegen Sporting Portugal. Presentator Pim Sedee blikt met Driessen en Ajax-volger Mike Verweij uitgebreid terug op die memorabele Champions League-avond. Maar wat moet Ajax doen als Davy Klaassen weer fit is? Wie moet er dan buiten de eerste 11 vallen? Ook wordt er in Kick-off vooruitgekeken naar de kraker van dit weekend: PSV-Feyenoord. Driessen en Verweij geven antwoord op de vraag wie een betere coach is, Arne Slot of Roger Schmidt. Dan een blik op het buitenland. Moet Donny van de Beek bij Manchester United vertrekken, zodra de transfermarkt weer open gaat? Ja, stelt Driessen. ,,Het is gewoon zielig om hem daar nu te zien spelen.'' Bij Barcelona staat de positie van coach Ronald Koeman onder druk, na de 0-3 oorwassing in de Champions League tegen Bayern München. Driessen: Jordi Cruijff heeft nee gezegd om Ronald Koeman op te volgen.''
Doug Haller, Arizona State writer for The Athletic, joined DJ & PK to talk about the Arizona State Sun Devils as they prepare to take on BYU Saturday night.
Wát een wedstrijd in Lissabon! Sporting werd met maar liefst 1-5 verslagen: een galavoorstelling! Uiteraard hebben Arco Gnocchi en Freek Jansen het daarover. Is Haller daadwerkelijk zo cool als hij doet voorkomen en is Berghuis nu echt bevrijd? En ohja, Ajax won ook van PEC Zwolle. Volg ons op Twitter en Instagram. See omnystudio.com/listener for privacy information.
Au menu de Radio Foot ce jeudi : Paris perdu ! Passif et défaillant, le 11 de Pochettino peut remercier Navas ! Coup d'arrêt d'un PSG qui ne prend qu'un point à Bruges, et frise la correctionnelle. - Apathique plutôt que galactique, on attendait beaucoup du trio d'attaque, réduit au duo avec la sortie de Mbappé en 2è mi-temps. Comment expliquer cette contre-performance ? - Bruges s'est montré enthousiaste et vaillant, l'adversaire était sans solutions. Un déficit physique ? Tactique ? - Pochettino réclame de la patience, comme ses joueurs, il veut garder un discours positif. - Le coach devra trouver la bonne formule face à Manchester City dans 12 jours. - Des Citizens bien partis qui ont flambé face à Leipzig (et encaissé un triplé de Nkunku). Des finalistes de mai 2021 déjà au rendez-vous ? - Haller frappe fort ! L'international ivoirien en feu sur la pelouse du Sporting s'offre un quadruplé pour ses débuts en C1 (et un doublé en 9 minutes), un beau succès 5-1 au final pour l'Ajax. - Patrice Beaumelle, un sélectionneur heureux ? Il reviendra avec nous sur la performance de l'ancien Auxerrois. - Pluie de buts à Anfield ! Les «Reds» sur courant alternatif, sortent vainqueurs du duel qui les opposaient au Milan AC, les «Rossoneri» ont vendu chèrement leur peau. - 1ère journée et bilan décevant pour les clubs espagnols. Le Real s'en sort in extremis sur le terrain de l'Inter qui a dominé son adversaire. Coaching payant d'Ancelotti ? Antoine Grognet reçoit Marc Libbra, Jean-Philippe Bouchard et Hervé Penot. Technique/Réalisation : Laurent Salerno, préparation : Pierre Guérin. 1er coup de sifflet 16h10 T.U.
The Matchday Live team review a thrilling night in the UEFA Champions League Group Stage with goals galore. We hear from Jack Grealish after Manchester City beat RB Leipzig 6-3 and also hear from Jurgen Klopp, Andy Robinson and match winner Jordan Henderson after Liverpool's 3-2 thrilling win over AC Milan at Anfield. Plus there were four goals for Ajax debutant Sebastien Haller in Lisbon.
Moderator: Lawrence A. DiDomenico, DPM, FACFAS Panelists: Sarah E. Haller, DPM, AACFAS; Brandon Lindberg, DPM, FACFAS; Jason R. Miller, DPM, FACFAS; Trudy K. Salmon, DPM, FACFAS Release Date: September 15, 2021 Run Time: 47min 38sec
Tony is joined by John Haller for an important discussion on some of the key issues and things occurring in the world right now. Biden and the Afghanistan withdraw, worker shortages, vaccination mandates, food shortages, madness in Australia and New Zealand ect
Weer een nieuwe podcast Kick-off, waarin chef voetbal Valentijn Driessen, Ajax-volger Mike Verweij en presentator Pim Sedee vooruitblikken op de Europese wedstrijden deze week. Volgens Valentijn en Mike moet Sporting Portugal woensdag te verslaan zijn voor Ajax, en verdient Sébastien Haller een kans in de basis. „Zeker na het vergeten vinkje vorig seizoen, en zijn rendement tot nu toe”, aldus Mike. Dat zou kunnen betekenen dat Steven Berghuis op de bank belandt. Die speelde aardig op '10' tegen PEC Zwolle. „Maar”, zo stelt Valentijn, „die moet zich nog veel meer laten gelden bij Ajax.” Ook wordt er uitgebreid gesproken met Robin Jongmans, die vanuit Spanje de verrichtingen van Barcelona volgt. Maakt die ploeg een kans als het dinsdag in Camp Nou aantreedt tegen Bayern München? En gaat Cristiano Ronaldo Manchester United kampioen van Engeland maken? Zijn debuut was in elk geval veelbelovend. Ook Mark van Bommel beleeft als coach van Wolfsburg een prachtige start in de Bundesliga. Verder alles over AZ en PSV, de horrorblessure van Liverpool-talent Harvey Elliot na een overtreding van Pascal Struijk en een prachtige Champions Leauge-wedstrijd voor scheidsrechter Serdar Gözübüyük.
Tyler and Jeremy talk about the Alan Haller hiring, File rants about Michigan's coordinators and how Harbaugh made a mistake and the guys talk about how, no matter the record, MSU's results are all on Tucker.
We dug into MSU's quarterback situation and what I think is happening there, plus the hiring of Alan Haller as MSU's AD. Then Northwestern football writer Louie Vaccher joined us to break down Friday's game against the Spartans. Plus, Harry Gagnon's college football picks and our can't-miss parlays.
Joining the show today: Matt Haller, Jennifer Brandeen, and Rikki Amos from the International Franchise Association. The team shares the most critical issues affecting franchising such as the PRO Act, Joint Employer, and an upcoming new economics report that will be shared with business owners about the value of the Franchise model. We also chat about the work the group is doing through the IFA Foundation, The Diversity Institute, VetFran, The Pride Council, and The Black Franchise Leadership Council. And, we'll get a preview of upcoming franchise events leading up to the 2022 Convention in San Diego! Thanks to Thryv, Constant Contact, and AnswerConnect. Shout out to IFA's partners at Franchise Update Media and MFV Expositions. See you in Vegas this week, and see you in NYC in September!
Michigan Federal District Court Judge Linda Parker issued a scathing, 110-page opinion sanctioning nine pro-Trump lawyers for their lawsuit that was an abuse of the judicial system designed to corruptly undermine Americans' faith and confidence in the results of the 2020 presidential election. Judge Parker also directed that her opinion be provided to the state bar authorities where each lawyer is admitted to practice for investigation and possible suspension and disbarment. Those nine lawyers are: Sidney Powell, L. Lin Wood, Emily Newman, Julia Z. Haller, Brandon Johnson, Scott Hagerstrom, Howard Kleinhendler, Gregor Rohl and Stefanie Lynn Junttila - names that should go down in infamy. For our Team Justice and Justice Matters merchandise shop, please visit: https://shop.spreadshirt.com/glennkirschner/ Please consider becoming a #TeamJustice patron at: https://www.patreon.com/glennkirschner My podcast, "Justice Matters with Glenn Kirschner" can be downloaded where you get your podcasts. To subscribe to the podcast: https://link.chtbl.com/JusticeMatters Follow me on: Twitter: https://www.twitter.com/glennkirschner2 Facebook: https://www.facebook.com/glennkirschner2 Instagram: https://www.instagram.com/glennkirschner2
"Hallo Haller" to nowy podcast w naTemat.pl. W piątym odcinku gościem prowadzącej Doroty Haller jest Ela Raczkowska, czyli dyrektorka generalna CEO Fundacji Vital Voices w Polsce. W rozmowie opowiada, skąd czerpie energię na dalsze wyzwania, gdzie szuka inspiracji oraz dlaczego wspieranie kobiet przynosi jej taką satysfakcję. Ela Raczkowska to kobieta, która robi coś dla innych kobiet, zwłaszcza tych najmłodszych. "Vital Voices" to program, który wspiera młode dziewczyny na początku swojej ścieżki zawodowej. W wywiadzie Raczkowska opowiada, dlaczego tak bardzo oddana jest programowi "Jestem Liderką" oraz o tym, jak próbuje zachęcić młode Polki do wiary w siebie, rozwoju i sięgania po więcej. Choć, jak sama podkreśla, praca to dla niej misja, a nie tylko kariera.
"Hallo Haller" to nasz nowy podcast w naTemat.pl. W czwartym odcinku gościem prowadzącej Doroty Haller jest Marta Macke, która pracuje w branży marketingowej i pasjonuje się narciarstwem. W rozmowie opowiada o ścieżce swojej kariery i o tym, jak udało jej się wyjść z kryzysu i przerobić to w swój największy sukces. – Miałam różne pomysły, co ze sobą zrobić, oczywiście nic z tych pomysłów, które miałam na poziomie studiów, nie wdrożyłam. Natomiast tak jak pewnie większość z nas, kompletnym przypadkiem trafiłam do reklamy – wyznała Marta Macke. W jej życiu zawodowym nie obyło się jednak bez porażek. – Nastąpił kryzys, biznesowy i gospodarczy. I był to też kryzys dla wielu osób, które musiały się pożegnać z pracą. Mnie również się to przytrafiło – opowiada. Choć było to bardzo trudne przeżycie, to pojawiło się "światełko w tunelu". Marta Macke swoją pasję połączyła z pracą.
In de nieuwe Kick-off, de voetbalpodcast van De Telegraaf, bespreken chef voetbal Valentijn Driessen en Ajax-volger Mike Verweij met presentator Kamran Ullah het laatste voetbalnieuws, met geregeld exclusieve nieuwtjes. Volgens Ajax-trainer Erik ten Hag is Ajax nog nadrukkelijk op zoek naar een nieuwe aanvallende impuls. Dat de selectie nog niet op orde is, vindt Driessen onvoorstelbaar: „Ajax is het aan zijn stand verplicht om in de zomer de selectie rond te hebben om zo mee te spelen voor overwintering in Europa.” Ook Verweij vindt het opmerkelijk dat Ajax voorlopig nog geen Plan B heeft na de afgeketste transfer van Kamaldeen Sulelmana. Natuurlijk gaat het ook over de eerste voorselectie van bondscoach Louis van Gaal. Volgens Verweij en Driessen kiest van Gaal op dit moment voor fitheid. „Het is logisch dat van Gaal uitkomt bij spelers van Feyenoord en PSV, die ploegen zijn al vol bezig en presteren ook nog eens goed”, aldus Driessen. Verder in de podcast: wie wordt er kampioen van Nederland? En heeft Hakim Ziyech het in zich om te slagen bij Chelsea?
"Hallo Haller" to nasz nowy podcast w naTemat.pl. W drugim odcinku gościem prowadzącej Doroty Haller jest Agnieszka Martyna-Ross – polska topmodelka, która robiła międzynarodową karierę w latach 90. W rozmowie opowiada o początkach swojej kariery, jak udało się jej wyrwać z małej miejscowości na Pomorzu Zachodnim i nie tylko. – Jestem dziewczyną z małego miasta, ze Szczecinka, zawsze wiedziałam, że to za małe miejsce dla mnie. Lata 90. to było nowe otwarcie. Dla mnie to była okazja, żeby zwiedzić świat – Agnieszka Martyna-Ross. Opowiada też, że kariera topmodelki była dla niej tylko drogą do spełnienia marzeń – Kwestia urody – bo przecież ten zawód wymaga specyficznej estetyki – była drugorzędna, ja po prostu miałam świadomość, że mam tzw. warunki. Ale ja nigdy nie miałam o sobie mniemania, że jestem jakaś szczególnie piękna. Ale to były drzwi do świata. Ja byłam go ciekawa i na przestrzeni 10-15 lat udało mi się zrealizować wszystkie moje marzenia – tłumaczy. Wyjaśnia też, jak została modelką. Jak wzięła los w swoje ręce. – W tamtym czasie na rynku funkcjonowała jeszcze moda polska. To był łącznik między Szczecinkiem a Warszawą. Najpierw trafiłam do mody polskiej i po prostu z ulicy przyszłam na Kubusia Puchatka (ulica w stolicy – red.) do pana Jerzego Antkowiaka i powiedziałam, że chcę zostać modelką. Po prostu – wspomina. Jak wyglądała dalej jej kariera? Co robiła już po zakończeniu jej? Posłuchajcie sami! Zapraszamy na drugi odcinek "Hallo Haller", w których Dorota Haller rozmawia z inspirującymi kobietami. Nowe odcinki w każdą środę o 20.00 na stronie głównej naTemat.pl, naszym kanale YouTube i Spotify. Zapraszamy!
Zapraszamy do "Hallo Haller" - nowego podcastu naTemat. Dorota Haller, prywatnie i zawodowo kobieta sukcesu, rozmawia z innymi silnymi kobietami o byciu... kobietą w dzisiejszych czasach. W pierwszym odcinku Anna Lewandowska.
Engpässe bei Lieferketten bereiten der europäischen Wirtschaft und gerade mittelständischen Unternehmen nicht nur wegen Corona enorme Probleme. “Ich sehe, dass ein Umdenken stattfindet. Von der überregionalen zur regionalen Produktion. Man sucht also regionale Lieferanten und baut Lagerbestände auf", sagt Dirk Oliver Haller. Während Materialien und Rohstoffe teurer geworden sind, stellt sich die Frage, woher die Liquidität kommen soll, um große Aufträge angehen zu können. “Liquidität ist das wichtigste, was ein Unternehmen vorhalten muss. Dann kann man auch auf Märkte reagieren. Ich erlebe immer wieder, dass Unternehmen große Aufträge bekommen und gar nicht die liquiden Mittel dafür haben. Und das war auch unsere Idee, dass wir Unternehmen unabhängig von Banken bei der Einkaufsfinanzierung helfen”, so der Gründer und Vorstand der Deutschen Finetrading AG. Alle Details wie Unternehmen durch die DFT liquide werden können, erfahren Sie im Interview von Inside Wirtschaft-Chefredakteur Manuel Koch und auf https://dft-ag.de
Seit Robert Haller die Geschicke des Bürgerspitals lenkt, werden die Weine immer besser und heute bezweifelt niemand mehr, dass das Bürgerspital in Franken und darüber hinaus zur absoluten Spitze gehört. Vor allem ist es dort in den vergangenen Jahren immer erfolgreicher gelungen, die großartigen Potenziale so einzigartiger Lagen wie dem Würzburger Stein und der Würzburger Stein-Harfe herauszuarbeiten und auf Flaschen zu füllen.
The PROTECT Study is testing how well an investigational medicine works in children and teens with type 1 diabetes. The hope is that this drug, called teplizumab, would help people continue making more of their own insulin and reduce the need for injections, have better glucose control and/or fewer complications of T1D. To enroll in the study, you need to be within six weeks of diagnosis. That's a tough time to make a big decision like this. We caught up with the Lahners family - 16 year old Alex just marked one year with T1D and he's spent almost that entire year in the PROTECT study. He and his father talk to Stacey about the decision to take part and what happens during this trial. Alex doesn't know whether he got the drug or a placebo, but he's only using six units of insulin or less a day! Info on the PROTECT study - including how to enroll Previous episode which included information on PROTECT In Tell Me Something Good - A big achievement for one of the first families Stacey found in the online community. ThisIsCaleb is a high school valedictorian! Learn more about Medicare coverage for Dexcom: www.dexcom.com/G6-Medicare This podcast is not intended as medical advice. If you have those kinds of questions, please contact your health care provider. Check out Stacey's book: The World's Worst Diabetes Mom! Join the Diabetes Connections Facebook Group! Sign up for our newsletter here ----- Use this link to get one free download and one free month of Audible, available to Diabetes Connections listeners! ----- Get the App and listen to Diabetes Connections wherever you go! Click here for iPhone Click here for Android Episode transcription below: Stacey Simms 0:00 Diabetes Connections is brought to you by Dario Health. Manage your blood glucose levels increase your possibilities by Gvoke Hypopen, the first premixed auto injector for very low blood sugar, and by Dexcom take control of your diabetes and live life to the fullest with Dexcom. This is Diabetes Connections with Stacey Simms. This week, imagine being newly diagnosed and having to decide right away whether to take part in a clinical trial. The protect trial is for kids and teens and needs to start within six weeks of diagnosis. Alex Lahners agreed to do it. Alex Lahners 0:42 I know that I don't want future people getting diabetes. And I didn't want anyone I knew to get diabetes. So I ultimately was like, I'm not just going to do this for myself. I want to do this for other people who are in the future going to be diagnosed. Stacey Simms 0:56 Alex is 16 he was diagnosed last year, he and his father talked to me about the decision to take part and what happens during this trial. And tell me something good. A big achievement for a kid I've never met but feel like I've known forever. One of the first families I found in the online community. This podcast is not intended as medical advice. If you have those kinds of questions, please contact your health care provider. Welcome to another week of the show. Always so glad to have you here. We aim to educate and inspire about diabetes with a focus on people who use insulin. My son Benny was diagnosed with type one right before he turned two. That's 14 and a half years ago. Now. My husband lives with type two diabetes. I don't have diabetes, I have a background in broadcasting. And that is how you get the podcast. I told you a couple of weeks ago, I had a meetup It was my first in person parent meetup since COVID. I used to do these things all the time. And I've done them for years, I run a large parenting Group here in the Charlotte, North Carolina area. And it felt so good to see people again and have these meetups. But what was amazing, and this is what I told you about is that two of the families, newer diagnosed already have their kids in clinical trials. And we live in Charlotte, which is not where a lot of these take place. So I was really impressed. And I think that obviously speaks to the access that we have. We have fabulous endocrinology groups. And we have really great outreach programs from JDRF here in our area. But I think it also speaks to the availability of these trials. These were not happening back when my son was diagnosed back in 2006. And I covered one of these trials though, and we're going to talk about today. I talked about this briefly in an episode a few weeks back with Dr. Henry Anholt from prevention, the group behind the protect study. And here's what he told us at the time. If you missed that episode, I will link it up. But in a nutshell, the protect study is involving about 300 children and adolescents. They're in clinics across the US, Canada and Europe, you have to be eight to 17 years old, you have to be diagnosed with Type One Diabetes in the previous six weeks. So as I said in the tea's it's really quick, you got to know you have it and get in here to the study really quickly. You have to be positive for one of five T1D auto antibodies, you have to produce a minimum of your own insulin, they do those two tests as part of the study. And then you need to be otherwise generally Healthy Kids in the study are placed into one of two treatment groups, two thirds of the participants will get the actual medication here and 1/3 will be assigned to the placebo group. It's decided at random and the medication in this is decided at random and it is blinded which means nobody not your child, not you not the doctor will know what group you are in. And the medication is going to sound familiar it is teplizumab This is the medication that we've been talking about for several years. That is in many trials that is in front of the FDA right now, as a prevention for type 1 diabetes. It's been shown to prevent the onset for a couple of years. This is a little different, though, right? This is using teplizumab in kids who are already diagnosed, seeing if they get it right away. What happens. So the Lahners family was kind enough to talk to us about their experience here and I'm going to go ahead and sort of spoil the ending because I was amazed by this. Alex is Benny's age he is 16 He is not a small kid, and he is using about six units of insulin a day, a day a day. If you're at all familiar with teenagers, it just sounds absurd. We would love to say of course just from that that the city is a big success the medication works for Get Out Of course, you know, quick look, they don't even know if he was actually in the the part of the group that got that to close him up. He could have gotten the placebo and I guess be in a very long honeymoon be a really exceptional case. I don't know. We will talk about it in just a moment. But first Diabetes Connections is brought to you By Gvoke Hypopen. our endo always told us that if you use insulin, you need to have emergency glucagon on hand as well. Low blood sugars are one thing we're usually able to treat those with fast acting glucose tabs or juice. But a very low blood sugar can be very frightening. Which is why I'm so glad there's a different option for emergency glucagon Gvoke Hypopen pen is pre mixed and ready to go with no visible needle, you pull off the red cap and push the yellow end on to bare skin and hold it for five seconds. That's it, find out more go to Diabetes Connections dot com and click on the Gvoke logo. Gvoke shouldn't be used in patients with pheochromocytoma or insulinoma visit Gvoke glucagon dot com slash risk. Alex and Jeremy, welcome to the show. Thanks for joining me. Thanks for having us. I'm really excited to learn more about your story. You know, it's it's interesting at the same age as my son, but very different circumstances before we get to the studies and to play the map and all that stuff. Jeremy, let me start with you. Tell me the diagnosis story. How did you know something was going on? Jeremy Lahners 6:03 Well, it was a, it was a warm summer night almost almost a year ago. Now, we had noticed over the course of really a couple of weeks that Alex just was not feeling well. And he's always done kind of a good job of hiding some of his symptoms from us a little bit. And he had just not been feeling well. He was drinking a lot of water and was sleeping a lot. Probably the sleeping was the thing that we noticed more than anything. He just wanted to sleep all the time. Now, school had just ended maybe a week or two prior to this. And a lot of what we saw as symptoms we really chalked up to a teenage kid wanting to just be left alone. Now that school was done and wanting to sleep all the time. So we we sort of wrote a lot of stuff off, we did take him in because he had had indicated he had some symptoms kind of leading up to some of all of this. And our doctor at the time, based on the way that we described things really thought that it was allergies. And so we started allergy medicine, then the day before we took him to the hospital, we just noticed that he was really looking thin. And he's a wrestler, he has lost weight over the course of the many years that he's been wrestling and so we know what weight loss looks like for him. But this was very unusual weight loss. And so I actually asked him to weigh in that evening, and he had lost over the course of about a four week period he had lost about 30 pounds. And as 150 pound kid at the time, you know, losing 20% of your body masses is a lot. The next morning, he got up and he just he looked like a ghost you know, fail thin. And Stacey Simms 7:53 Alex, do you remember how you felt? Alex Lahners 7:56 I vividly remember all of this. I remember when it first started happening like that said I was drinking a ton of water. And it really just felt like my tongue was constantly sandpaper. And I would pour like, I pour water into my mouth and it would just wouldn't go away. And I was just drinking so much water. I think my water intake like quadrupled, or more. And it was really odd. I've never loved drinking water. But I think that was the first time I was like, Oh my gosh, give me all the water I can have. Stacey Simms 8:29 What did you think when you got on the scale? I mean, 30 pounds is extreme. I Alex Lahners 8:34 knew that I was losing weight. I knew that I'd lost weight and you know, every sickness you sometimes you just lose weight. But when I got on the scale, and I think I said I was at 134. And I had previously weighed in like 160 something. Yeah, I was that's not right. I remember weighing myself a second time, just to make sure. And it came up with the same number. And I was like, it's I went downstairs I told my dad I was like it says I'm 134. And we couldn't believe in I remember everyone like my mom, my dad and maybe someone else who was there. We were all just like really shocked at how much weight I had lost. Jeremy Lahners 9:11 Like I said, the next morning he woke up and just look real thin. And so we took him to the ER, we kind of had decided that was that was the line where it just something was clearly off. We didn't know what it was. They ran all of their tests, and probably within 20 minutes or so they came back and said, we're not sure exactly what's going on. But by the way, your son is a diabetic that could Yeah, I mean it was it was very kind of in passing a little bit. And I remember, you know, this was all during COVID. So only one parent could be with him at the time. So I'm texting my wife, and I'm texting her I said they're saying that Alex has diabetes, and she says there's zero chance of that. Tell them to rerun tests because they have no idea Do what they're talking about. They came back in and said, Yeah, his blood sugar is at 588. And that's tremendously high. He's clearly diabetic, we think you should probably take care of this problem. They put us on an ambulance and drove us down to the pediatric hospital in Charlotte. And we spent three days in the ICU, and they were able to get his blood sugar recovered, of course. And it was just a massive, massive crash course in all things type 1 diabetes. At that point, Stacey Simms 10:31 I didn't really have the opportunity often Alex to talk to you know, a newer diagnosed teenager who actually wants to talk about this stuff. I have to ask you, how difficult was it? I assume in the hospital, they made you do your own shots? And had you figure everything out? You know, what was that like? So give yourself the first injection. Alex Lahners 10:48 Honestly, when you first get diagnosed, or at least when I got first diagnosed, I got really lucky because I have some people around me who I had known previously, who were type one diabetic, I got extremely lucky with having resources to reach out to and people to talk to, I have always released previously to diabetes, I had always hated needles, shots, I hated everything. But obviously, getting diagnosed with diabetes, you kind of have to learn to get over it. I just kind of put it in my arm. And I was like, this is going to be a new reality for me, and I just accepted it. And I never I don't think I remember feeling any sort of way with how the injection felt or how it made me feel. I think it was just kind of like a, this is how it's gonna be. Stacey Simms 11:30 So you leave the hospital, you go back to trying to figure out how to do life now with diabetes. But your experience took a turn in that you pretty quickly got involved in a pretty cool clinical trial. Jeremy, how did you find out about the protect study? Jeremy Lahners 11:46 Well, we sort of jumped headfirst into things, the nurses at the hospital were outstanding and, and gave us all the wonderful material on on jdrf, I reached out to our local jdrf contact to submit Alex's paperwork and material and whatnot. And, of course, that put us on the mailing list of the various jdrf webinars and things that are going on and we follow it on Facebook, join the Charlotte type 1 diabetes parents group, all those types of things, we sort of dove headfirst into all of those resources. Within maybe a week or so I happened to see a webinar about that was upcoming about this protect study. And we thought, well, we should we should at least listen in we we weren't really convinced that it was a great idea at the time. But we figured we're in this now we need to at least listen to what's happening in the space a little bit and try to participate. You know, it was hard enough, sort of coming to grips with all the things coming at us. But we really did want to try to educate ourselves on on the various medical things that were going on. So that was what led us up to listening to the the details of the protect study. Stacey Simms 13:04 So what was involved? Tell me, you know, we haven't been involved in a clinical trial, much to my son's regret. He's always pushing me to get him in and we just haven't been successful. After all these years, I keep trying. So can you share with us a little bit of the process? Because it's not a local study? Right back to Jeremy, but first Diabetes Connections is brought to you by Dario health. And one of the things that makes diabetes management difficult for us that is very annoying to me and to Benny. It isn't actually the big picture stuff. It's all the little tasks adding up. Are you sick of running at a strips, do you need some direction or encouragement going forward with your diabetes management, with visibility into your trends help you on your wellness journey? The Dario diabetes success plan offers all of that and more. No more waiting in line at the pharmacy. No more searching online for answers. No more wondering about how you're doing with your blood sugar levels, find out more go to my daario.com forward slash diabetes dash connections. Now back to Jeremy as he starts to take us into their study experience. I had asked him about whether there was a local site it wasn't a local study. Jeremy Lahners 14:20 It's not it is a nationwide study. However, the nearest facilities to us were far from local. I think our nearest facility is technically Atlanta. But we had the opportunity during the the webinar they were interviewing Dr. Haller out of the University of Florida. And he was describing this protect study on to plumas AB and we thought it was a good study for Alex the sort of entry criteria for the study. They were accepting children kids under 17 years if I if I remember correctly, who either Were pre diagnosis or had been diagnosed within the last 45 days. So that immediately qualified us, I reached out during the webinar using chat tools inside the zoom to say, My son was just diagnosed, we'd like to learn more. And Dr. Haller reached out to us via email. The next day, we had a zoom call with just him a day or two later. And he talked to us in a lot more detail about how the study goes and and provided some options for us. So that was all the sort of pre work if you will, from there, we did take a day or two and, and we sat down as a family and talked about whether it, it made sense for Alex to participate. Both my wife and I had participated in some medical research studies. When we were in college, there was a paid program at our college, that you could take participation in some of those programs. So we had a background in it. And I think we were both pretty encouraging of Alex to participate in in the study. But, you know, Alex was 15, at the time, and we felt he was old enough and mature enough that he should really make the decision. And so we didn't leave it up to him, maybe with some heavy encouragement. But nonetheless, it was his call at the end of the day. And we would have supported that Stacey Simms 16:27 Alex had to make the decision. What were you thinking? Alex Lahners 16:29 So the decision was really, honestly hard for me at the time, I was still trying to get over like, just recently being diagnosed and trying to get everything under control, just to understand what was happening to my body. Ultimately, it boiled down to not only had mom and dad done, I guess, trial before they've done studies before, but I don't think anyone who has type 1 diabetes would tell you, oh, yeah, you should go out and get type 1 diabetes. It just it sucks. It's, it really is not fun. I thought if I would have had someone else 50 years ago, been able to prevent or tell me that I was going to get diabetes and have a drug to prevent the onset of diabetes, I would have taken it in a heartbeat, I would have done whatever it was. And I know that I don't want future people getting diabetes, and anyone I knew to get diabetes. So I ultimately it was like, I'm not just gonna do this for myself. I want to do this for other people who are future in the future going to be diagnosed or are going to be diagnosed later. I guess. Stacey Simms 17:36 That's really a wonderful sentiment. I mean, Jeremy, I don't need to tell you this. Alex, you're, you know, you're so well spoken and really mature about all of this. So thank you very much for for sharing that. We can be goofy later, I'm sure. So Jeremy, you fill out the forms or do whatever you need to do what happened in this trial. This is not a survey, this is a go to Florida, go to the hospital, get a treatment, what happens? Jeremy Lahners 17:59 We went down to Florida a couple days early so that Alex could get a COVID test. I think he was the first person in our family to get one of the touch your brain nose swabs. He really enjoyed that, I'm sure. And then we started the study. The study was sorry, the the first part of the infusion was 12 straight days of infusion. Generally, it was anywhere from three to four hours per day. We typically did that first thing in the morning. And thankfully, number one, Alex was at a school so it didn't interrupt school. Number two, my job is flexible enough that I was able to fulfill my work duties in the afternoons and evenings. So it really all worked out for us very much a perfect storm of good, if you will. But for 12 days straight we did the study, the infusion, and that first 12 days was probably the roughest simply because going in you don't know. It's a blind study. So you don't know if you're getting the drug or not. You could be getting the placebo. So there's a lot of trepidation and a lot of do I really want to go through all of this pain multiple times through if all I'm getting is the placebo? We really had a lot of conversation about, you know, what's this going to look like in six months or a year? That was ultimately the study we did, because of the nature of this drug. It is an immunosuppressive. So we did have to quarantine especially again, given it was the COVID times we really had the quarantine. We spent a lot of time in the hotel room just hanging out and like he does Alex slept a lot. That was the two weeks that we spend down there. Stacey Simms 19:49 Oh, it's was it painful at all? I mean, is it just a blessing? Just I mean, is it just an IV and the pain is just sometimes when you get an IV put in that hurts, or is there more to it Alex Lahners 19:59 honestly It's really just the IV, they do a great job of like, counting you down, like, they'll be like, Alright, we're gonna put dive in, you know, take a breath 123, and then they'll put it in, I have never had problems with it hurting too much. I still like clench my fist and my jaw when they put it in, because you know, I don't like needles, but it only lasts for maybe 10 seconds at the most. And it is really fast. And once it's in, everything else is super easy. They tape it to your arm, so it doesn't move, and there's no chance of it being pulled out. And they're just super careful when either the placebo or the supplements AB is injected into you. It just felt like there was cold, I would say water running through my body, and you get this salty taste in your mouth. But besides that, that's all I can notice. Stacey Simms 20:52 Well, and I know. And Alex, as you mentioned, they they're very careful. They're very good. And Jeremy, when you and I spoke previously, you really said that this was a top notch staff, let me just give you a moment to give them the kudos that you had already mentioned to me off air. Jeremy Lahners 21:06 Sure. I can't go into the details of how good a crew they really are. As much as I love our primary endocrinologist, she does a wonderful job with us here in Charlotte, having the opportunity to spend 12 straight days with an active scientist of the study of diabetes, good or bad than sort of being locked in a room with us for a period of time while they administered the drug to Alex, it really gave us an opportunity as a newly diagnosed type one family to ask a lot of questions for, like I said, 12 days straight. We had access to Dr. Haller, and the other doctors plus all of their nurses and assistants, some of whom also have type 1 diabetes. And we were just able to ask all of the questions that are just reeling around in our heads. And all of them had been through different experiences, or had treated patients with different experiences. And they were just able to answer so so many questions, so many of the fears that we had as parents and I think fears on Alex's behalf as being a newly diagnosed patient were so easily allayed as a result of just being able to spend so much quality time with such good individuals. Stacey Simms 22:33 What happened after this, you you came home? I mean, I feel like I know the ending to the story. And you're spoiling a little bit in my introduction in that it doesn't seem like you've got the placebo, it seems like things are working out, let's just say very differently for Alex than for a typical teenager, in the first year of his diabetes. Is that safe to say Jeremy Lahners 22:53 it is? And admittedly we don't know for sure. One of the disadvantages of participating in the study when we did was there's still that honeymoon period that many kids go through and and so a lot of what we experienced very early on was still questioning, are we just seeing the effects of honeymoon? Or are we seeing the effects of this study drug because his his insulin requirements have been very, very low. That really just continued, we would go back to Florida every four to six weeks, and do blood draws and just a quick one day blood draw to test absorption. So no more drug was ever injected. In fact, his next injection is coming up in about six weeks. But again, he just he seemed to stay in what we thought as new parents to be the the honeymoon period. And even today, nearly a year later, that's still where we're at, we're still kind of in this wonderful period where his insulin requirements are insanely low. From what I've heard from other parents. Stacey Simms 24:02 Let's talk about that. Give me an example. Alex Lahners 24:05 I currently have heard from my primary endocrinologist that a kid my size and just my age would probably take around 60 to 80 units a day, somewhere around there. I think I am currently sitting at total daily usage of like 6.4 units a day. So that's, you know, a 10th Stacey Simms 24:28 I don't want to get too personal. But would you mind giving us approximate weight and height? I mean, you're 16 years? Alex Lahners 24:35 Absolutely. I'm 16 I'm probably around 178 pounds right now and I'm about 510. So generally speaking, I should be taking substantial more amounts of insulin than I am not tiny, though. He's got a small kid. Stacey Simms 24:52 I'm not even sure what to ask Jeremy and Alex because you without knowing the typical experience. It's I'm not quite sure we know What to ask you in terms I keep, I put it this way. And I'm stuttering around because I can't ask you what's the difference? Because you? Yeah, you don't know. I mean, my son is 16. He's 215 and almost six feet tall, which is great for wrestlers. We know everything about your bodies. We know how big you are, we know tall you are, when you weigh on a daily basis, but you know, and he probably uses definitely 80 units of insulin a day. I mean, it's, it's just remarkable. So how do you treat it? Do you I know you were an insulin pump? Can you use it? I mean, Alex Lahners 25:30 oh, I do use my insulin pump. But the good thing about my insulin pump is and especially just the T slim in general, is it's all programmable. And you can set it up by yourself. So I have to set my insulin crazy low. And I have to make these crazy schedules. Because when I first got diagnosed, I think I was on a one to five, ratio of units to carbs. And then I hit my honeymoon phase. And my endo backed it off to one to 15. And I was like, Oh, yeah, this is awesome. And I remember I went out and ate like a fast food burger. And I took like, obviously, like a third of the insulin that I've normally taken, I was like, This is great. And then as time progressed, it just kept needing to be moved back, because I would take too much insulin, and I would get low. And I was constantly fighting lows. And I still have that problem today. So there was a time where I was at a one to 100 carb ratio. And I am currently at a one to add carb ratio. And I have to space out when my pump gives me insulin, because if it gives me insulin, like a correction dose throughout the entire day, the amount of insulin that I need to correct is so low that my pump won't let me put it in. So I have to default to the smallest amount which is like point 100 units of insulin in order to correction me down to where I need to be. That's your that's your basal rate. That's my basal. Yeah, so Jeremy Lahners 27:00 his basal is point one units. And I think right now you're on every other hour. Yeah, every other hour. So Stacey Simms 27:07 every other hours zero. So you go like a point one and then a 0.0. Yeah, that's amazing. I don't want to get too far ahead of everything here. And Alex, I hope this continues for you, you know, indefinitely. But Jeremy, what is the goal of this study to see kind of how long they can extend this honeymoon or keep these insulin uses low? Or, you know, what is the hope of they expressed it to you? Or do you kind of just take it, you know, month by month, Jeremy Lahners 27:34 what they described to us very early on was that some of their participants, were seeing this honeymoon period effectively extend for two to three, sometimes even up to four years. That was really kind of the goal. When we started, as we look at where Alex was in his sort of mature ation process. We sort of thought, you know, if Alex could get through high school, and maybe well into college, still on the honeymoon period, that would be a wonderful experience for him, he'd still have the opportunity to do all of the sort of traditional things that you think of without necessarily significantly having to worry about his diagnosis. That was our mentality going in. I've heard suggestions that possibly there's maybe kind of a continuing dose that you can get over the course of, you know, follow on years. But that wasn't part of the study or anything that we did, Stacey Simms 28:32 they are still looking for about 40 people for this study. This is for new onset, folks with type one. What would you say if somebody's listening, they found the podcast pretty quickly. And they're debating, is this something that you all would do again, because you said it. I mean, there's like I said, it's not as easy as you stay home and take a pill this may involve travel is definitely involves two weeks time and a lot of pokes. Jeremy Lahners 28:57 Yeah, I mean, looking back, if given the opportunity, again, I would, we would jump on it in a heartbeat. I would say anybody who has the opportunity, and the ability to take the time to do this study, not just the drug itself, but again, the time with the doctors, the combination of those two things is nearly invaluable. So to me that there's no way that that I would turn down that experience again, even if Alex would have gotten the placebo. I mean, ultimately, even if he would have gotten the placebo, he was still gonna end up in the same condition just sooner. So at the very least the time that we got to spend with the doctors has paid for itself trillions of times over. I guess maybe the other thing that's that's worth noting is these are paid studies. So Alex got a little bit of money to spend on his car and turning 16 he he got a little bit of money to spend towards that mostly on gas. So there is some monetary value to it. As well, that's that's worth mentioning. But that wasn't our purpose by any means. It was really the drug and the opportunity to spend time with the doctors would be my two key selling points. Stacey Simms 30:12 You don't have to go on the record with this question. But can I ask you how much it paid? Jeremy Lahners 30:17 It paid? I believe it was right in the neighborhood of $75 per day of visit. Stacey Simms 30:25 I mean, it wasn't $5,000 No, no, I want to be clear when people are you know, we're thinking about it. I wish Yeah. No doubt. It's a lot of gas. Jeremy Lahners 30:34 They'll spend it. But But yes, no, it's not quite that much. But, I mean, hey, you know, absolutely, yeah. So we go back the end of July. And that will be our next two week visit. We've had a couple of visits since then, about every six weeks or so. We take a one day trip to Florida, just to do checkups. But otherwise, this will be the next big one. And then I think from there, if I remember correctly, I think our next visit is six months afterwards. Stacey Simms 31:09 All right, Alex, I have two non study related questions for you. Absolutely. How do you keep your gear on when you wrestled? What do you do with your diabetes Alex Lahners 31:18 stuff? Obviously, that was a really big thing. When I first got diagnosed and learning that you're going to have all this stuff stuck to the side of you, it was like, people are going to grab that when I wrestle. And especially at a high school level, at a varsity level, there is no holding back. If you have a knee brace or anything, people are just going to attack that. That's what I've learned throughout the 12 or 13 years that I've been wrestling, I just was like really worried at the start. But I learned that if I was able to at least keep it close, and you know, tight enough in and you know, obviously you wrestled well, and got off the mat sooner than you wouldn't have any problems. The way that I wrestle with my stuff is I have my Dexcom that's always on and never take that off for any reason. Never even take the transmitter out unless I'm changing the transmitter or changing my sight. For my T slim though, I just disconnected it and I'd put a stop in, I learned that the adhesive is just as good as the Dexcom adhesive. And if I kept it more on my torso every once in a while I'd put it on my legs. But if I kept it more on my torso, because the singlets are just so tight, it just kind of glues everything to you. And I never really had a problem, I think the biggest part was locations as to where you would want to put your stuff. Obviously, if I put it on like the back of my arm, that's a more high risk area, because that's a very frequent place for people to grab while you're wrestling. So I would put it on the upper part of my thigh, kind of closer to my groin or upper groin, and I would just put it in there. And that's where I would leave it. When I put my singlet on, obviously, I'd pull it up. But a big problem for me was writing like the singlet would write up my leg and I didn't want it to pull off. So sometimes I would just pull my singlet just barely above or right on the infusion site so that I could just keep it there. And if it did pull up, it wouldn't pull my site off. Stacey Simms 33:20 Do you use anything to wrap it but or anything or everything just kind of sticks, okay, because of your locations. Generally, Alex Lahners 33:26 I only use like over patches, I use like two Dexcom ones. And I think we had some like aftermarket ones, whenever the Dexcom ones would run out, unless it was like on my arm or something of the sorts, I wouldn't wrap it. But if it was on my arm, or I just didn't have any other choice, and it was in a very vulnerable area where I felt like it was about to come off. I would always wrap it with just some like simple athletic gauze. And then I put some athletic tape around it. And that always seemed to hold it. I also have a little like sleeve that I use for swimming and I guess for sometimes athletics, and I just would slip that on over it. It was like a dry fit sleeve. And that worked perfectly to Jeremy Lahners 34:08 we did wrap your leg the first couple of times, but really, we found it wasn't necessary. So we sort of stopped doing that by the end of the season. Stacey Simms 34:17 My second question for you was telling me about the socks. Alex Lahners 34:21 So with Dr. Haller, I learned that we have a very similar passion for extremely crazy socks, because I wrestle I love wearing weird socks because there's only two things that there's three things that you can really change to differentiate yourself from the rest of everyone. It's your singlet, your shoes and your socks. When you're wrestling on a team or just for your school. There's set singlets so the main biggest thing, you can't get to change, you don't get to change it all right. And for shoes, there are some flashy shoes but really sometimes they get extremely expensive if you're going to customize them there. Similar to basketball shoes, so I decided the cheaper option, and the only one that I really had left was socks. So I started a while ago, just getting tons of weird socks and funny socks. I have, you know, pizza socks. Right now I'm wearing these weird math socks that say five out of four people are bad at math. Stuff of the sorts, I walked into the study for this two week study. And on the first day, I met with Dr. Haller, and he noticed my socks, I don't remember what socks I was wearing. Exactly. But he also showed me that he was wearing some like, funny diabetes socks. And from then on, we've just had this competition to outdo each other, even when he's not in the room physically. Like with me, like if there's a different endocrinologist in that day, he will send them pictures of his socks in order to show me to try and one up me, but I like to think that I'm ahead. And if he's listening, I want him to know I will be winning the SOC battle. Stacey Simms 36:01 Before he let you go. Jeremy, you have said and I forgot to ask you have said that. While he uses so little insulin you do? I guess. I don't know. I don't know if I'm struggling because I was gonna say this is a downside, I guess it is, you guys have still struggled with low blood sugars Is that something that you are still dealing with? Jeremy Lahners 36:20 It is the struggle that we run into right now is again, because his settings are so low, right now, it's very easy for him to go low. We don't struggle with highs too much at all. And even when he does go a little bit high, he comes back down very quickly. But seemingly every day, I would say almost every day. He has a slight low episode. And and even overnight, you know, we'll we'll have to wake him up sometimes and say, Hey, buddy, you're, you're low, you know, eat some sugar. And he'll groan at us and tell us that we're wrong. But nonetheless, that is probably the one downside that we have seen. And And listen, we'll take that downside all day long. But that has been probably the one downside that we've struggled with a bit. Stacey Simms 37:09 Alex and Jeremy, thank you so much for joining me, it's great to talk to you it was really interesting was really fun. And, you know, thanks for spending so much time with me and my listeners. Thank you, Stacey, this has been great. And I really should say thank you as well for doing the study. These studies are so important. And Alex, as you said earlier in the interview, people who take the time to do this aren't necessarily helping themselves, but they are helping the people yet to come. So I would be remiss if I wasn't thanking you and thanking your family for taking the time and the effort in going through all of this. So I think I speak for all of my listeners when I say thank you so much for taking part in this study. It's our pleasure. You're listening to Diabetes Connections with Stacey Simms. Much More information at Diabetes connections.com or in the show notes wherever you are listening. And they are still looking for kids for this study. So I will link up more information. If you know someone who has just been diagnosed if somebody is maybe going through trial net or the jdrf testing for you know a sibling or another family member has type one, and they want to find out if they haven't, this is the kind of thing where they have to get in so early, it's really hard to find people. So they are still recruiting. It was amazing to talk to this family and find out what their experience was like because boy, 16 years old, and using that little insulin really just makes you sit up a little bit straighter. I mean, that would make a very big difference. Gosh, all right, much more to come. And again, you can always go to the website or show notes to find the links, find the transcription and share this with a friends because you never know who might know somebody who could be in the trial coming up. We've got Tell me something good. But first Diabetes Connections is brought to you by Dexcom. And I get a lot of questions about Dexcom coverage for people on Medicare. And why not it's not as though you stopped needing a CGM, the minute you turn 65 The good news is that the Dexcom g six continuous glucose monitoring system is covered for Medicare patients who meet the coverage criteria. If you have either type one or type two diabetes and intensively managed insulin, you may be covered. To find out more about what that means that if you qualify check out dexcom.com backslash g six dash Medicare. I will link that up with this episode. You don't have to write it down. You're going to want to talk to your doctor and you may even be able to get your Dexcom supplies at the pharmacy saving time and money learn more again it's dexcom.com backslash g six dash Medicare. In Tell me something good this week is scrolling through Facebook as one does and a bunch of graduation pictures caught my eye now this time of year of course there's so many beautiful prom and graduation pictures and I'm so happy for all the kids and you know as my kids have And older we've grown up with so many people who are now sharing their beautiful graduations and prom pictures. But I had to stop because Lorraine Sisto posted pictures of Caleb. Now, those of you who had kids diagnosed around the same time as I did or earlier, or kids were diagnosed like 2006 2007. During the heyday of blogging, it really just started. There weren't that many, but it was growing. And man in the next couple of years, there were hundreds of diabetes blogs that so many of us met each other. And now of course, there's 1000s of Instagram accounts and social media stuff, and it's changed and it's still great to connect. But there are some moms and I think you know, who you are, that I connected with in the community and we may have never met I never met Lorraine in person. And as the kids have gotten older, we have kind of communicated to online a lot less. But I have basically watched these kids grow up and Caleb her son was diagnosed just one month after Benny. Benny was diagnosed in December of 2006. Caleb was diagnosed I think he said, He's obviously a year or two older since he just graduated high school, but he was diagnosed in January of 2007. So we have been in this together for a long time. And I have watched her post these pictures of this fantastic kid and sharing so much information. And so I will link up her blog she hasn't written in a while. But if you have a small child, and you want to see a real go getter of a kid who met Nick Jonas, they just did so many wonderful things. And she shared a lot of great information over the years that's still really relevant. But I'm talking too much because the reason I wanted to share all this is because it Caleb's graduation picture, he graduated as the valedictorian of his class, holy cow. He's going to school for engineering, he is strongly considering biomedical to research type one, I mean, just fantastic. So congratulations, Caleb, congratulations, Lorraine and to your whole family. He's got a brother and a sister and she shared about them as well. I think it's really important to include the siblings too, but so many fabulous graduation stories this year. And if you've ever read this is Caleb or you want to look back on what blogging was all about back in the heyday of diabetes blogging, I will link that up as well. If you have a Tell me something good story, feel free to reach out I might stumble upon on on Facebook again. But you can always find me Stacy at Diabetes connections.com or reach out and our Facebook group Diabetes Connections, the group. Before I let you go, a couple of quick notes on the next couple of weeks are gonna be really interesting on the show, late June, early July, I have some late breaking types of interviews. So stay tuned on social, I'm gonna be posting and Diabetes Connections, the group on Facebook, with the behind the scenes stuff, I don't believe there's gonna be any scheduled disruptions. But you never know. So stay tuned on that some of the stuff is embargoed. I can't talk about it. It's technology news, as you can imagine, and I just want to get it to you as quickly as possible. podcasting is tough that way. It's not exactly an immediate medium, you know, like radio, but I do my best. So I'll keep you posted on that. I will be friends for life. That is July 7 through the 10th. And I'm always excited to go and this year more than ever, just because this is the first for me diabetes conference that I'm going to be going to in person since COVID. I cannot wait and I'm doing a new presentation called reframe your diabetes parenting brain. I will be sharing more about that in the weeks to come. But basically, I do this online anyway, do this in my local group too. When somebody posts mom fail and talks about what they did and how they messed up their kids diabetes, I try to reframe it and show them how they really did a good thing. I mean, he wrote a whole book about it, so why not? And then, as I'm taping this episode, we are getting Benny ready for his trip to Israel. I have talked about this on and off for the last year on this show. Many of you know how nervous I am about this. As you listen as this episode goes live, he has gone he is away he has started his trip. And I don't know that I'm going to get too much sleep. Because while he goes away to camp every summer for a month, and while he's with fabulous people that I trust, he's not with us and He is very far away. So I'm probably not going to speak about it or post about it very much because many of you know me, I'm very superstitious, but I cannot wait till after when he is home and after I hug him. I will see if he wants to talk about how it went diabetes wise and hopefully we can report back. Oh my goodness, I'm you guys know, I'm just I'm so nervous. I'm so excited for him. But this is really hard for me. All right. Thank you, as always to my editor, John Bukenas from audio editing solutions. Thank you so much for listening. We've got Diabetes Connections in the news every Wednesday 430 live on Facebook and then here on the podcast on Fridays. So hopefully I'll see you back here for that until then be kind to yourself. Benny 44:52 Diabetes Connections is a production of Stacey Simms Media. All rights reserved. All wrongs avenged
This week we sit down with Brad Waldron, founder of Kali Protectives to take a deep dive into helmet tech and the new Grit gravel helmet. Kali Protectives Web / Instagram Support the Podcast The Ridership Automated Transcription, please excuse the typos: Kali Protectives Craig Dalton: [00:00:00] Hello and welcome to The Gravel Ride podcast. I'm your host Craig Dalton this week on the podcast. We've got Brad Waldron from Kali. Protectives talking to us about helmets. [00:00:15]Before we jump in just to reminder, The Gravel Ride podcast is sponsored by listeners like you and a select group of sponsors from the industry and outside the industry. We appreciate any contributions to the show's www.buymeacoffee.com/thegravelride. And when we do bring a sponsor on board, please make sure to check out their products because without their support, we couldn't continue doing what we're doing. [00:00:40] [00:00:40]With that said let's dive right into my interview with Kali. Protectives. Brad. Welcome to the show. [00:00:46] Brad Waldron: [00:00:46] Thanks for having me [00:00:47] Craig Dalton: [00:00:47] I'm super stoked to talk helmets. It's interesting. It's one of those categories that. I haven't covered on the podcast thus far. So I figured going to an expert and talking about it will give the listener a lot of value about helmet technology for gravel, riding [00:01:02]Brad Waldron: [00:01:02] looking forward to it. [00:01:04] Craig Dalton: [00:01:04] Why don't you start off by telling us a little bit about your background and how Kali was started? [00:01:09]Brad Waldron: [00:01:09] Sure. I was super lucky in a previous life career. I worked for an aerospace company working on military aircraft. So I was a carbon fiber R and D engineer. Mostly on the process side, not on the material side. [00:01:22]I was fortunate enough to work on the B2 bomber F eighteens joint strike fighter, and then a few airplanes that had never made it, but just stuff you've made it and broke it to see what we could do. And this will give you the idea of my age, but I was at Northrop Grumman in between the first Gulf war and the second Gulf war. [00:01:41] And they didn't want to put a lot of money in production at that time, but they want to put a lot of money into R and D. So I was just in the perfect place at the perfect time where you could almost do anything you wanted. If it made sense. I, one time my boss walked in and said, DARPA's going to be here next week. [00:01:57] Think of something. Go back to my desk and I, without five different projects and the next week sit down in front of these generals and you. Present these ideas in here I'm, in my late twenties, early thirties, somewhere in there. And they're like rubber stamping, all of them and oh shit. [00:02:12] Now I got, I do, so I got to build a $12 million milling machine and then just things like that. So that's where my real just try it. Mentality came from, when you hear are, you can't do that. And get into some of the things that people told me we couldn't do at Kali. It's let's just try, and that's been like theme sentence. [00:02:30] So I worked that and through some changes in life, I went to work or another aerospace company and didn't love it, so I was down in the Southern California area, working there. And then I moved back up to Northern California where I was born and raised. And I was in R and D at this satellite company and it just wasn't everything I wanted. [00:02:49] And lo and behold, there's this ad for the big red S in the paper. And so I put on my suit and went to my interview. Nobody's wearing a suit, got called back for a second interview and go, what do I wear when I knew I wore the suit? Yeah. So I guess it worked, they offered me a job as the Pumps and locks, designer, something like that. [00:03:09]And I was so happy to take my 25% pay cut to be in the bike industry. And there was, and then on my first day they said, Hey, you know that job, we offered you the helmet guy quit. And would you rather that job on the helmets over locks? Hell yeah. But the ironic thing was they, at that time, specialized was still assembling the helmets at, on a site and. [00:03:32] We tested our helmets and they said, there's the test lab. There's 10,000 helmets sitting over there that can't be shipped. So you say they're tested and Don, w oh, and by the way that the helmet technician quit at the same time. And so I walked into this test lab with this equipment I never seen in my life and go, okay, what did we do here? [00:03:50] And fortunately somebody who's become a good friend and who I trust in testing. Dr. Terry Smith came and trained me how to run the equipment. The best thing I did was I tested all the helmets at specialized for the next year. I didn't hire another technician. So getting that lab experience and seeing how these helmets broke personally, not just people come and say, Hey, look at this, here's your, reading reports and stuff it's was a great launching point for [00:04:17] me. [00:04:18] Yeah, absolutely. I can imagine just having your hands on that many. Tests to see how these helmets are performing just was like training by fire. [00:04:27]I tell people frequently that I'm a mediocre engineer. I'm really a better technician. I just somehow wiggled my way to get my degree, but mostly I just love being in the shop. [00:04:36] If you saw my office next to me as a drill press on the other side of the bandsaw, just being out there with my hands is the way [00:04:44] Craig Dalton: [00:04:44] I work. And did you have a background at cycling when you were in the aerospace industry? [00:04:48] Brad Waldron: [00:04:48] I had started cycling with some friends and just, around the LA area. [00:04:52] And if, I lived in first and Palmdale. When I first moved into Palmdale, I walked into a bike shop and this long hair blonde guy walks up and says, can I help you? And I said I'm new to the area. Can tell me where some trails are. And he's I'll pick you up Saturday morning at nine, it turned out it was insane. [00:05:10] Wayne crows Dale. So my first ride was insane, Wayne, and he there's a long story on board with it all, but he basically rode a wheelie up the fire road next to me, up and up. And, but we had a, the time rode with Wayne A. Little bit and then, got into riding there. And then the transfer down further. [00:05:29] Into the depths of LA, where you have to drive an hour just to get to the dirt. lot of people around me were riding and that's where I really got started riding was during that. [00:05:39] Craig Dalton: [00:05:39] Yeah. Right on. And you brought that to specialize and obviously specialized has a big riding culture down there in Morgan hill. [00:05:45] Brad Waldron: [00:05:45] Yep. Yeah. We're actually about 500 meters from them. Our building is they actually have to pass us to get to their building. And so we painted big ass Cali letters all over the building. Just to annoy him. [00:05:58]Craig Dalton: [00:05:58] So then at some point you decided I'm going to jump off and do this on my own. What, was there a particular market opportunity that you saw? [00:06:05] Something that you felt wasn't being done at the bigger companies? [00:06:08] Brad Waldron: [00:06:08] No, not yet. That's not really where it happened. At the time when I was in special ed, so I had moved on from helmets and eventually became the head of engineering that specialized for everything for bikes. Mostly. What I concentrated on was the carbon fiber projects. [00:06:22]The the, I worked on the tarmac and Robi mostly on the layups and things like that. Other guys who had much better frame experience than I did you know, the geometry? So I would go the factories and work with the carbon layups and things like that. And we would make it and break it. I still have, I have tarmac frame, number two, doesn't look, anything like what went to production. [00:06:43]It had a split top tube who knew that was UCI illegal, but so my re people see it all the time. It doesn't say special. I didn't say anything on it. So it's got carbon, top tube and chains and seats tubes, and and then the underbody is aluminum. So the idea was it was going to be nice, crisp, feel of the aluminum, but where your body touches, you're going to have that forgiving carbon fiber Conceptually feel. [00:07:09] And so I still have that bike when people see me out on it I'm not a big roadie. I don't ride a lot on the road, but they're like, what the hell is that? Because it's totally unrecognizable, but it's pretty cool. So I actually left specialized primarily because they were going through some transitions at the time they had wanted to transfer a lot of the engineering to Taiwan. [00:07:32] And I wasn't interested in that job. I had my first kid, I didn't want to travel, did not want to travel at all. And so I actually resigned from the position. It was a great experience. It took me nine months to leave. Because I didn't have another job. I hired my replacement. I finished those two bikes and then just started consulting a little bit. [00:07:52] So I consulted. A little bit with true beta worked on their first carbon bars. With Jared Smith, they're headed for engineering their first carbon cranks, things like that. And it bounced around a little bit. Then somebody came to me and said, we need a carbon fiber factory in China to feed these other factories. [00:08:12] And I just quit specialized cause I didn't want to travel. And they came to me and said, Hey, can you help us start the Stackery? And I'm like, how many times a year will I have to come? Then they were four times. I'm like four, okay. Talking to a non traveler. Now I said, I can come for four times a year. I spent no less than 150 days a year for the next seven years. [00:08:33]I just couldn't let it go, try to get the thing up and running and working the way. And we made things like skid plates and pipe bards. KTM was one of our biggest customers. But one of our customers was a helping it factory. So they came to us to make a motorcycle helmet shell, and they, we looked at this thing and we made the shell, we sent it over. [00:08:52]And they knew I also had some testing background. They were showing me these test results. And I was seeing some things that I didn't like. Basically I was seeing a double spike in G-Force and what that meant to me, it was inside your school or your brains just slapping around. Cause you're seeing a double impact. [00:09:10]That was happening because as the impact hits the outer shell was so stiff that if you forced a spike up, then as the shell breaks down, they start to fall. Then you hit the foam and they spike up again. I'm like okay, what's doing, that is the gap between your foam and my shell. [00:09:27]Let's get this thing tighter. Arrive, for example, really prides themselves on the fact that they designed their foam and shell to fit so well. Not everybody spends that much time on it. Then I had this really, according to them, stupid idea. He said, why aren't you in molding these like the bike helmet? [00:09:43] And they're like, that's impossible. It's a processing problem. You'll never make it work. And that's where that let's just try it thing came in. So we went in and we tried it. It took a couple of years to finally get it to work, but we started in molding motorcycle helmet. So now you're eliminating that gap between the farm and shop. [00:10:03] Then on top of it, you start to learn, oh, I don't need that much shell. I can thin the shell down because I've got the phone, backing it up. And by the way, I don't even have to have as high of DPS density. I can lower that too. So now I'm finding out that when I have the impact, instead of having that double spike and G-forces, I've got this nice smooth curve that spreads the load much more efficiently, then I got less shell. [00:10:29] I got lighter foam. I got a much lighter helmet. And I always liked to tell people I never start a project with a weight goal. I think that's not a good way to start a project that, that compromises safety in my opinion. But that process was helping us make a much lighter helmet, which in the end is simple physics force equals mass times acceleration, reduce the mass. [00:10:51] You're going to reduce the force. So we started, Perfecting this process showing these results around, tried to sell the patent. I did not. I was not looking to start my own company. That being a CEO, being in sales and marketing, not my favorite thing. We had a few people who were really close to buying it and then backed off. [00:11:11] And then somebody who somebody came along a golden investor, essentially. Came along and said, you got to do this and I'll back you. And so I've got one silent investor in his company has been nothing but amazing. Always allowing me to make safety decisions first over simply. What are your sales today? [00:11:30]Craig Dalton: [00:11:30] You mentioned that's amazing. You mentioned that you started with that motorcycle helmets technology did Cali launch where the motorcycle [00:11:39]Brad Waldron: [00:11:39] we did and nobody cared. Literally we, we went to the Interbike of Moda, which was Indianapolis. There was in Indianapolis motor sports show and we got our booth and I'm standing there my first day. [00:11:52] And you could hear the yarn from the industry. Nobody cared, had the cutouts, you could see. So the second day I'm like, I spent all of my money to get here. I stood in the aisle and made people pick up the helmet. Cause it was significantly lighter. Then what people were used to, and, know, you get the response, like that's it's okay. [00:12:09] But I guess just put it in your hands and if you don't want to talk to me, move on and then you put it in their hands and go, what is this? And then through that, the rest of the next few days, I only had one guy actually put it in my hand and walk on. Everybody else said, all right, what's going on? [00:12:22] And then we would explain what was happening with the in molding process and why we could do what we could do and, and show the results of the [00:12:30] Craig Dalton: [00:12:30] testing. Was it always in the back of your head to move into the cycling market? [00:12:35]Brad Waldron: [00:12:35] I was more of a cyclist than I was Moto. When I started doing good, if I get involved with something, I want to get into the sport. [00:12:41] So when we started making skid plates and pipe guards, I went and bought motorcycles, started riding dirt bikes. Now I ride a Ducati and in a fixer and and but cycling was definitely more my heart. But it, so it wasn't that I was necessarily looking to do that, but we had found a way to build full shell helmets that I believe in, I drank my own Kool-Aid that when you put that on your head using that technology, you were putting on a safer product on your head. [00:13:11] So the next thing of course was to do a full face download on it. So we did that and immediately the bike industry was. More welcoming. Yeah. The motor industry is great, but it's complex. It's the distributors have all had their own helmet brands. So in our industry, we've got the different distributors BTI, K Chaz QBP, all these different guys. [00:13:34] They don't have their own brands. When you start talking about Modo, they all have their own Hammad brands. If you think. The answer for example, is open owned by a company called Rocky. There's just the complexity of getting past the house brands where, when you were finding people were interested in our conversations. [00:13:51]We'd go to Interbike and people wanted to talk to us. They wanted to hear about what we had and yeah, and that's where we really started taking it off is when we were having these one-on-one conversations, it wasn't through any advertising. We did it. Wasn't through. The talk, it was meeting people and just showing them what we did and answering questions. [00:14:10]And that philosophy is still super important to us today. You call Kelly today. You better get somebody on the phone, somebody better to answer the phone. Cause that's our, we want to talk to people and respond. And that's an important part of who we are. So [00:14:24] Craig Dalton: [00:14:24] is it safe to say that the sort of signals the bike industry was giving you around the full face helmet suggested, Hey. [00:14:30] We need to lean into this and create a range of helmets for cyclists. [00:14:34]Brad Waldron: [00:14:34] Yeah. It came into, when you started talking to shops and what their needs are it's one thing to walk in with one helmet, it, when you're going up against, but let's be honest, you're going up against track, specialized, giant Cannondale, Scott, these guys all have, all their products behind them. [00:14:52]And they all have helmets and there's incentives to bring in those helmets. You get a discount if you bring that in. Then the only, other, not the only, but the other big boys would in are, bell Jiro who do have a complete range, that doesn't leave a lot of room for a lot of other people. [00:15:04] So expanding your range and it's something that makes sense for a shop carry. I still love bike shops. I still love walking in and smell the rubber. And still today Over 90% of our sales are still two independent bike dealers. Our, the amount that sold online is small. And that's a whole nother, probably podcast to talk about how that continues. [00:15:29] But our main focus is still to, to maintain those relationships with those independent bike shops. [00:15:35] Craig Dalton: [00:15:35] Interesting. So when you develop that range and I guess we can slip into the. More road and gravel helmets that you guys have been releasing over the few years. What features were you leaning into at that point? [00:15:46]You talked about how originally the differentiator turned out to be the weight and the technology around protecting the head and maybe a different way than had been done. Where did that go to for the road slash gravel helmets? [00:15:59] Brad Waldron: [00:15:59] Sure. Really what's what continues to drive us as technology. [00:16:02] We're always looking for stuff that can help us make. The next step. And we started with a technology from a guy from Australia called conehead, where you got the geometric shapes inside these helmets and they crushed the, but to get more specific to answering your question, some of the difficulties, when you start talking about road, helmets is ventilation is so important, right? [00:16:24] So getting big vents, getting air flow through. When you do that, you have to really crank up the density of the foam to get the enough to stop the impact according to the standards. When you do that let me put it another way to start with this. I believe all helmets are too hard. [00:16:41] We're hurting people by the foam densities. We need to get the foam densities down. It's based on how the interpretation of the standards are, which are built to take the worst of the worst crashes. We're not doing enough to deal with them. Where the majority of crashes are, which are according to a study at the Imperial college of London. [00:16:59]80% of all bicycle accidents are below 160. G's, yet all I got to do to pass a test and sell you a helmet is go to the test lab and make sure it doesn't go over 300 GS. Now 300 GS is close to death. Alrighty. How do we address both of those big hits? But also the majority of those hits. [00:17:21] And so that's where, that's where a lot of my time gets focused on. It's not specifically for a genre of helmet per se, but how do we lower the density of the foam? How do we put stuff next to your head? That's softer. How do we start reducing impact at zero G's? So now I jumped back to the question of how do we deal with the gravel helmets? [00:17:45]Again, now I'm battling. I got to put a lot of foam in a small space, which means I got to Jack up the densities. What's cool. Even though a lot of people don't know about Kali, we're known within the industry and the other helmet companies know each other. But getting a reputation is it somebody who wants to try technology? [00:18:03] We get people coming to us all the time saying, Hey, you want to try this? And my answer is always the same. If it works right, you bet. I'm going to try it. W we were approached initially by Don Morgan, that physicist from Australia with the corn head later, we were approached with a from a chemical company out of Italy that had this carbon nano to acrylic based material that they were trying to pitch as a multi impact material. [00:18:27]It didn't work as multi impact, but it works. So now I can bind the code ed and EPS. And I'm finding I'm able to lower the density in the helmet that we're probably going to talk about, which is the grit. And so much that I was shocked at the first round of testing that I was expecting the typical results where I got to put it way too hard, the higher density, if I'm in a place that I don't really want to put it, but by putting the right materials in the right combinations I'm getting better results then than I expected. [00:19:03]Craig Dalton: [00:19:03] And so did that sort of Eureka moment happened early in the process and allow you then to pursue different elements of the design? [00:19:11]Brad Waldron: [00:19:11] It wish she was at easy. We actually took, originally took that structure that I talked about and put it in an Aero helmet. And the other way I can go with this stuff is I can. [00:19:24] If you look at our Tada helmet, it's an Aero helmet. I think I've sold a hundred of them, so I don't think you've seen it. Probably. I think we have it on the Danish road team. So unless you've been there Copenhagen lately, I'm not sure you've seen this helmet, but if you actually look at it and you look at cross-section of it, it's one of the finished how much you've ever seen. [00:19:43]Which was interesting. For me as an engineer, that I could actually get this thing to work and pass the test. But because passing the test is not my goal. My goal is saving lives. Maybe cheeky about that, but it really is what we give a shit about. We want people to get on their bikes and ride more. [00:20:04]I want to get on my bike and ride more. I've been helicoptered off the hill before we want that to happen, but when I went back to more. Realistic thicknesses and I could drive those foam densities down. Now I'm getting the results I want and not only on linear impacts, but rotational impacts and I'll skip back. [00:20:24] We're doing a lot of testing and outside labs. So we took some of our helmets. We put in MIPS in it. We put in what we call Rian, which is our low density layer. That's Material developed by a professor out of London. We put in like five different anti-rotation systems and we tested them against each other. [00:20:42] And they all do an interesting job. A little better here, a little better there. Sometimes this system works, sometimes this is the work better. What consistently worked better was we threw in a. Helmet with extremely low density in it. It's actually a homophobic. We sell in Europe, but can't sell here because the density is too low and that helmet consistently performed way better in rotational forces. [00:21:06] So all these systems that we put in help, but what really matters is put softer shit next to your head. Let's get these things to be more crushing and more the pillow's a little bit overrated, but just get that stuff that will crush next to your head. So when I'm talking about using the nano material in the Coneheads structures, I'm basically talking about a way in a much smaller area to get the foam density down where it's really making a difference for you during that crash. [00:21:37] Craig Dalton: [00:21:37] Is that right? A way to articulate upon impact how a Cali helmet performs versus kind of maybe a major brand helmet in terms of how it crushes how the materials work? [00:21:48] Brad Waldron: [00:21:48] Sure. I don't know how to say it. It's that I can say, I'll go continue to go back to that foam density thing. Most people don't put as much energy as we do in trying to find how to get to that lower density. [00:22:01] So basically if the density is too hard, that thing you're going to smack and it's going to crack cracking is fine and a big hit on the helmet cause that's releasing energy. But what I really want is I want it to crush. And I wanted to crush equally. And then by having those, like those geometric shapes in that center, it's actually, if you look at it, it looks like an Oreo because the nanomaterials white, you've got the black DPS around it. [00:22:25] And as that outer side crushes, then you hit another material that's meant to crush and send the energy laterally away from your head in those geometric structures. Rather than a smack and a crack, you're just seeing a progressive crack with multiple different materials there to help dissipate that energy. [00:22:44] Craig Dalton: [00:22:44] Yeah. That resonates with me. And it's, it's hard to visualize in a conversation at times for the listener potentially. But if you think about that, just the, I think the pillow analogy works for me where it's just progressively becoming more and more supportive as my head is unfortunately impacting the ground or dirt, wherever I'm riding. [00:23:01]Brad Waldron: [00:23:01] And, a lot of your impacts are small. And so you don't even get into the part, but it has to really, get harder and harder to stop that big hit. And that's my kind of, my complaint with the way that our testing is that, we're only testing for those big hits. [00:23:16]When we have, a lot of hits, we're actually hurting people by doing it the way we're doing it. So w we just got to look at it from all aspects, rather than just. Th there's one test that we do in the test lab. Yeah. [00:23:27] Craig Dalton: [00:23:27] I managed to ring my own bell, this pandemic on a gravel ride. So I've it's resonating with me that having a look, it wasn't a super devastating crash, but I had one of those impacts that I definitely rung my bell. [00:23:41] Definitely like maybe it was not concussed, but needed to be escorted home by a friend. [00:23:47] Brad Waldron: [00:23:47] Some level of brain trauma happened there. It might've been like, but something happened. Yeah. It happens at a surprisingly low amount of G-forces and that's why I keep talking about, we need to start managing those impacts from all levels, not just from the highest levels. [00:24:06] Craig Dalton: [00:24:06] Yeah. And you said that you said before, like the testing is just very. With the tests, one thing, and it's easy to design around that one thing without really thinking about the athlete and the impacts. [00:24:17] Brad Waldron: [00:24:17] Yeah. Our tests are based on tests that were done in, in, in 1973 where we dropped cadavers on their heads and measured for skull fracture. [00:24:27] Cause we didn't know enough to measure the brain trauma. And at that time we terminate that it took 300, G's a helmet. It head took 300 GS to crack the school. So that became. Where that 300 GS came from it's cracking your skull, and that was fine at the time, but we've moved on. We have better technology and people are trying, people are trying to make changes. [00:24:46]People ask me about MIPS and I always say, I respect them. What Dr. Haller did was taught us about rotational forces. And we've learned a lot about those rotational forces. I happened to have a different philosophy on how to manage those. Then what MIPS does, because I want to start with something softer next year, head, they use a slip plane thing that is between your head and the EPS that needs. [00:25:12] Yeah, I was going to [00:25:12] Craig Dalton: [00:25:12] say, I think a number of listeners might be familiar with MIPS as a technology because it has been pretty heavily marketed and it's that little plastic frame inside the helmet that is designed to move. Yeah. [00:25:23] Brad Waldron: [00:25:23] Yep. Yes. And in my test it works. It's a technology that, that works. [00:25:28]Again, I, it, I think there's another way to attack it and we do by using something that crushes more immediately and then it gets off the rotation, but I'll even go beyond that. Forget my systems, my low density layers versus MIPS versus somebody else's. What I found in my tests at the university of Strasburg and that dynamic research and other labs that we use our own labs is the lower you can make the foam, the lower density. [00:25:56] You can make the foam the better it performs in rotation as well. So that salt. What's off your shit next to your head [00:26:05] Craig Dalton: [00:26:05] keeps coming back to that, Brad, doesn't it [00:26:07] Brad Waldron: [00:26:07] really what it comes down to, it's not as simple is that right? Otherwise we just put something, we go use those old ProTech helmets that just, had the soft stuff in it. [00:26:14]Those bottom out and they do bottom out at a low number you're in trouble. So we have to, we're trying to manage, all the impacts and that's, what's hard. I had somebody at MIPS. Tell me once. Those are two different helmets and I'm like, You guys invented the anti-rotation thing. [00:26:29] We're smarter than that. We can do this, just different philosophies. Yeah. So [00:26:33] Craig Dalton: [00:26:33] all this culminated recently in the grit helmet, coming to market, is there anything you want to mention about that helmet that we haven't covered? [00:26:40]Brad Waldron: [00:26:40] Yeah. The grit was it, there's pressure that pressure. [00:26:45] There's a lot of requests from our distributors, especially in Europe that. So look at the road side of things. I'm I'm a dirt guy through and through. And we the grit got the name. We actually started, the name was called the nickname was the dirty road. And we saw that as something that was much more Cali. [00:27:04] Then if we said, oh, we're going to go try and put a helmet on it on a tour de France rider. We got a couple of helmets that are in that category that they the UNO and the grit, the UNO is like a hundred dollar helmet. It's nice. It was actually designed by Hildegard Mueller. [00:27:20] Hilgard was the head of design for JIRA for, he was a Gero for 20 years. I don't know how long he was head of design, but. And then, and he freelances now and he helped us with that design. Because as you know is primarily amount biker. And when the lights, gravity a lot our line had led, leaned that way for a long time. [00:27:38] And then the grit was designed by Alan O Kimora who I've worked with quite a bit. And he's former bell specialized worked on several specialized road helmets. But we really worked on these thinking more towards the gravel market than the road market, because it fit us and who we are more than you're saying, like I said, we're going to, we're going to go sponsor. [00:28:03] I was like saying sky because they're dead and they're not a team anymore, but it's just, something like that and more to, to what we are. Yep. [00:28:11] Craig Dalton: [00:28:11] And you certainly have some great athletes riding the helmets on the gravel scene, former guest and friend of the pod. Amanda Nauman is a great friend of Cali's. [00:28:21] Brad Waldron: [00:28:21] She's just super chill and rides like a monster. You know what she did at the XL. Just shows that and, just a great attitude and somebody that's fun to just watch and see her progress. [00:28:33] Craig Dalton: [00:28:33] Yeah. Yeah. It was a great racing debut for the helmet. For sure. [00:28:37]Brad Waldron: [00:28:37] Appreciate that. [00:28:39] Yeah. [00:28:39] Craig Dalton: [00:28:39] Cool. Brett, I appreciate the overview. I hope the listener got a bit out of this in terms of the type of helmet tech that they should be looking at. I think I'm probably guilty of not looking at my helmet enough and saying, Hey, it's time for a new one time to replace it. So this is a good reminder, this conversation to to think about what's hanging in the garage. [00:28:58]Brad Waldron: [00:28:58] Yeah. Do you want to keep that thing for us, especially if you're using it a lot. And it's not saying that it's not always has to be a Cali there's other helmets, there's other people making helmets they're out there like me that. Give a shit that want people to do well. [00:29:11]We have our philosophy and like I said earlier, I drink my Kool-Aid. I think what we're doing is right on and on target. But yeah, make sure that you're, taking a look at what you're putting on your [00:29:19] Craig Dalton: [00:29:19] head. Sure. And I'll make sure that the listener knows how to find you. [00:29:23]Brad Waldron: [00:29:23] I appreciate that. [00:29:24]Craig Dalton: [00:29:24] So that's it for this week's edition of the gravel ride podcast. I hope you learned a lot more about helmets than you did prior to listening. I know I did. [00:29:33]It's an area. I probably should be thinking a little bit more about given the state of my current helmet. [00:29:38]Thank you for spending a little bit of your week with me this week. If you're interested in giving us any feedback or joining our community, please visit the ridership it's www.theridership.com. Until next time. Here's to finding some dirt under your wheels
Join us as we hear from sophomore Ava Astilla and freshman Kevin Haller. Our student spotlight segment highlights students at Cardinal Gibbons High School who live the mission of Gibbons through their leadership. Listen to students from various grades and programs as they come together to share their insights and experiences with the greater Gibbons community. Thank you to our students for taking the time to join us for our student spotlight, we are better because of the time we spent with you!
When defence attorney Mickey Haller is pulled over by police, the body of a client is discovered in the trunk of his Lincoln. Haller is charged with murder and can't make the $5 million bail slapped on him by a vindictive judge. Haller knows he's been framed and elects to defend himself.Best selling author Michael Connelly chats to Simon and Matt from Las Vegas. He is perhaps best known for his books featuring LAPD Detective Hieronymus "Harry" Bosch and criminal defence attorney Mickey Haller. Connelly is the bestselling author of 31 novels and one work of non-fiction, with over 74 million copies of his books sold worldwide and translated into 40 foreign languages. His first novel, The Black Echo, won the Mystery Writers of America Edgar Award for Best First Novel in 1992. In 2002, Clint Eastwood directed and starred in the movie adaptation of Connelly's 1997 novel, Blood Work. In March 2011, the movie adaptation of Connelly's novel The Lincoln Lawyer starred Matthew McConaughey as Mickey Haller. See acast.com/privacy for privacy and opt-out information.
Big news for Bigfoot Biomedical as the US FDA approves their insulin pen cap system called Unity – which also includes a CGM and an app. CEO Jeffrey Brewer explains what Unity is all about, gives us an update on Bigfoot’s pump system and opens up about his family’s story – his son was diagnosed almost 20 years ago. Plus, in Stacey's first in-person diabetes meetup since COVID, she observed something very interesting about the newer families. This podcast is not intended as medical advice. If you have those kinds of questions, please contact your health care provider. Check out Stacey's book: The World's Worst Diabetes Mom! Join the Diabetes Connections Facebook Group! Sign up for our newsletter here ----- Use this link to get one free download and one free month of Audible, available to Diabetes Connections listeners! ----- Get the App and listen to Diabetes Connections wherever you go! Episode Transcription below: Click here for iPhone Click here for Android Stacey Simms 0:00 Diabetes Connections is brought to you by Dario health. Manage your blood glucose levels increase your possibilities by Gvoke Hypopen, the first premixed auto injector for very low blood sugar and by Dexcom help make knowledge your superpower with the Dexcom G6 continuous glucose monitoring system. Announcer 0:24 This is Diabetes Connections with Stacey Simms. Stacey Simms 0:29 This week, big news from Bigfoot - FDA approval for their insulin pen cap system called Unity, which also includes a CGM and an app. CEO Jeffrey Brewer says their bundle approach is a bit like Apple’s Jeffrey Brewer 0:42 Apple takes a bunch of different pieces, some of which they licensed and some of which they make and integrates them into the most usable package that actually is going to be accessible to the most people. That's the way we think about it as well. Stacey Simms 0:56 Brewer shares what Unity is all about gives us an update on Bigfoot’s pump system and opens up about his family story. His son was diagnosed almost 20 years ago, plus my first in person diabetes meetup since COVID, where I got good news beyond just seeing my people. This podcast is not intended as medical advice. If you have those kinds of questions, please contact your health care provider. Welcome to another week of the show. I am always so glad to have you here. You know, we aim to educate and inspire about diabetes with a focus on people who use insulin. And when I started Diabetes Connections in the summer of 2015 this week's guest Jeffrey Brewer was my second guest, it is hard to describe what the diabetes technology situation was six years ago. If you were around then you probably remember especially this podcast audience, you know, I tried to talk about it, as I mentioned in the teaser, had a meetup last week with some local parents, which was fantastic. And I'll tell you more about that later. And a mom of a child diagnosed in January of this year asked me what DIY was all about. she'd heard about loop he heard about do it yourself. She wasn't quite sure what it was all about. So that was a long and winding conversation. If you are brand new, and you want to learn more, I recommend searching out the we are not waiting episodes of this podcast. And you can easily search those up at Diabetes connections.com. There's a search box on the upper right. It's a very robust search of our almost 400 episodes now. And you can search we are not waiting as all one word. I've put that in all of those kind of DIY open APS CGM in the cloud. You know all of those types of episodes. I know that six years ago, this pen cap system is not the Bigfoot FDA approval many of us thought would come through First, if you've been following this story for a while Bigfoot was founded in 2014. It was under a different name. It got the Bigfoot name in 2015. But it was founded by a small group of dads of children with type 1 diabetes, including Bryan Mazlish, who got that nickname Bigfoot via reporter looking for the elusive person Bryan who had developed a do it yourself closed loop which his wife and son with type one were using, and the initial headlines for Bigfoot, were all about bringing that closed loop system to market you can go back and see their initial funding press releases, which say things like you know, “the funding will support final development activities for Bigfoot’s Smart loop, automated insulin delivery service, the world's first Internet of Things medical device system delivered as a monthly service.” Bigfoot Unity, which is what we're talking about today is going to launch as that monthly service. It's such a great idea to cut down on the complexity, it's going to help so many people on multiple daily injections, but I know that this podcast audience leans very much into the pump closed loop give me all the tech news group. And I think it's important to acknowledge that that said, My guest is Bigfoot CEO Jeffrey Brewer. His son was diagnosed with type one in 2002 and as the former CEO of JDRF. Brewer led the artificial pancreas project there. In life before diabetes, Brewer founded and led early.com startups including city search and goto.com. We will find out all about Bigfoot Unity in just a moment but first Diabetes Connections is brought to you by Gvoke Hypopen and you know low blood sugar feels horrible. You can get shaky and sweaty or even feel like you're going to pass out there are a lot of symptoms and they can be different for everyone. I'm so glad we have a different option to treat very low blood sugar. Gvoke Hypopen is the first auto injector to treat very low blood sugar fever. Gvoke Hypopen is pre mixed and ready to go with no visible needle. before Gvoke, people needed to go through a lot of steps to get glucagon treatments ready to be used. This made emergency situations even more challenging and stressful. This is so much better. I'm grateful we have it on hand. Find out more go to Diabetes connections.com and click on the Gvoke logo. Gvoke shouldn't be used in patients with pheochromocytoma or insulinoma visit Gvoke Glucagon dot com slash risk. Jeffrey, thank you so much for joining me, I really appreciate it. Jeffrey Brewer 5:05 Thanks for having me. Glad to be here. Stacey Simms 5:07 So I looked back at my notes, you were my second guest on Diabetes Connections back in the summer of 2015, talking about the big plans for Bigfoot and holistic systems, and then lots of things that you said at the time you couldn't really talk too much about. And now here we are. So first of all, thanks for being my guest way back when when, you know, probably have three people listening, I really appreciate that. Jeffrey Brewer 5:29 Well, thank you, and thanks for sticking with us maybe took us a little bit longer than I had hoped. But we're finally here to be able to offer something to people with diabetes, that we hope it's going to improve life and make it a little easier. Stacey Simms 5:43 Definitely. Well, let's talk about that. So we're talking about Bigfoot Unity, would you mind kind of going through who it's for what it does, this is a system that is going to help people who are on multiple daily injections. So what is big for Unity? Jeffrey Brewer 5:57 Yeah, so as you know, had Bigfoot developing a range of solutions to help people whose lives are dependent upon insulin to live safely and, and hopefully better lives. We are in this journey, focusing first on multiple daily injections, basically, intensive insulin therapy, once a day, have a basal insulin, and then given shots at mealtimes, or for corrections of rapid acting insulin, that particular therapy, which about 3 million people in the United States today do on a daily basis, about half people with type two diabetes, about half people with type one diabetes, but it's really the same therapy, we have developed a system that we believe solves a lot of the problems that therapy has, when it comes to the ability of people to determine the right dose for themselves on an ongoing basis, and also for health care providers to support them in doing so over a long period of time. I Stacey Simms 6:53 totally understand because years ago, my son wanted to take an insulin pump break, he has used an insulin pump, since he was two, really six months after diagnosis, we got him on a pump. And we were so frustrated. Because not only did we have to do all the math manually that the insulin pump had done, there wasn't. And this was really before, there were lots of apps and things, there was no way to do all the stuff that the pump does in terms of insulin on board, and that kind of thing. So I assume that those are just a few of the features that Unity will provide Jeffrey Brewer 7:23 some of the things that a pump does BigfootUnity will help to support your right that for people taking shots, it's mostly a glucometer, a piece of paper with some instructions and a couple of insulin pens. There isn't a lot of technology involved in those people's lives right now. And what we've done is develop a package of technologies that includes some devices, and some software that is knitted together for ease of use, to make life convenient for the person to first of all, be prescribed the therapy to be trained how to use the therapy easily and safely, and then to over time be supported by a healthcare provider who has the responsibility of supporting many of these patients, we are bringing technology to a population of people who I think have been largely overlooked, because most of the innovations have been focused on pumps. And that's really been focused on type one and also focused on very highly engaged people with diabetes that frankly, had to do a lot more in order to support the therapy and seen by doctors who are very excited about the technology. But not everybody sees a clinician like that. And not everybody wants to put everything into their insulin therapy that maybe a pump would require. Stacey Simms 8:42 So take me through a little bit of it if you could, when I looked at it, I was kind of making notes that I wrote white cap black cap. So the white cap is for the fast acting and that gives you a dose, like a pump would say here's the suggested dose. Jeffrey Brewer 8:56 Sure Bigfoot Unity is a bunch of different things together at the centerpiece of the system is these taps that are going to be for the particular insulin that a person is prescribed, whether it is an insulin made by Novo Nordisk or Sanofi or Eli Lilly, we have caps that fit all the different disposable insulin pens for both the basal insulin and the rapid acting insulin. First of all, you get these caps that fit the insulin that you've been prescribed. You also get a couple freestyle Li braise, you get a blood glucose meter that talks to the caps as well. You get in this first time experience kit, everything down to the pen needles and the alcohol swabs that are going to be used for parasite before you put on a sensor, literally everything that you need in order to initiate multiple daily injection therapy with the exception of the Insulet itself. It's all in this box. So this box comes to a person with diabetes in their home. We train them to use the system through a digital interface that we've developed support. onboarding to our system but also for people who are cgmp may never have bought a CGM before will literally through a zoom interface, walk them through the first experience with CGM, and then train them on the whole system. And the centerpiece of the system, as I said, as these caps, which basically do a simple thing they keep track of when you last gave yourself insulin. And they do calculations that are necessary in order to recommend how much to take based on your doctor's direction, very simply on the blackcap, which is focused on the basal insulin, you have one button, and you can only press the button and cycle through screens. So you press the button. first screen says this is when you last took the dose. So it could have been say 23 hours ago, and it's time to take another dose, you press the button again, and it's going to tell you how much you should take. And that's what you were prescribed by your healthcare provider. And what can be updated in the cloud, by your healthcare provider. Rapid acting cap, the white cap is got some additional functionality, but still works the same way. It's got a screen on it, and then you press the button, the first screen is going to have when you last gave a shot, which is particularly important for stacking insulin as you refer to insulin on board. This is one of the big challenges that people who are on shots have is that they don't have a record of when they last took the shot. And so actually making sure that they don't treat the same high glucose reading too quickly, and then end up with too much insulin and end up low. This is something that we help with by actually keeping a person from stacking insulin. So you press this button, it's going to tell you when the last took a dose, if within three hours, you had taken a dose previously, it's going to lock out a correction. And therefore you're not going to make that mistake. This cap also interfaces directly with the freestyle library to or a blood glucose meter, and basically takes that data and directly translates it into a correction dose if you are taking your correction based on again what your healthcare provider had prescribed. So whether it's a correction factor or a sliding scale that was written down on a piece of paper, you don't have to remember or do any calculations, it basically just takes the number from the libri and turns it into here's how much insulin I should take. And if I had previously taken insulin that keeps me from over insulinizing and stacking insulin Stacey Simms 12:16 over insulinizing? Is that an actual word? Jeffrey Brewer 12:22 Yeah, I think I heard that from one of the researchers one time, so Stacey Simms 12:25 we're claiming it if it's not, it's a rage bolus or it’s over-insulinizing Unknown Speaker 12:29 There you go. Stacey Simms 12:30 I didn't mean to interrupt you, sorry. Jeffrey Brewer 12:32 No, no worries, the next step, after you take a correction, maybe you're going to have a meal. And having recommendation for how to dose from mealtime. It actually turns out that small, medium and large is a format that a lot of people are able to understand and work with in terms of how to take carbohydrate content and actually correlate that with an insulin dose. It's actually the minority of people, even in type one, but certainly with type two that carb counts. And so thinking about this in a different way, and a simpler way, where you have maybe small medium and large buckets, and a corresponding number of units for insulin that shows up right on the pen cap. If you want to add the two together, you are going to click the button again. And then it's going to basically add a correction to whatever the meal bolus would be, you're going to pick that value that you're choosing as a patient, because we're not deciding for you, we're just telling you, here's what your doctor would recommend based on all the calculations that you usually would do, if you had to do them. If your doctor were sitting there with you, this is what he or she would recommend you do. But if you know more, because for instance, you know, you're going to be exercising vigorously later, and you want to protect against hyperglycemia a person might decide to take a year or two less. But basically we're going to get them all the information that we can take it and make it actionable for them take as many steps out as we can to just get them to the answer they want. Because I don't actually think people want to know what their blood sugar is. They want to know, what do I What should I do? How much insulin Should I take. And so every step we can remove, and every thing we can take out of this equation to make it easier for people to stay healthy and take the right amount of insulin and then forget about diabetes for another four hours until another meal. That's what we're trying to do. And we're trying to do that for people who take shots, which is most of the world in terms of multiple daily injection therapy is the preponderant therapy for intensive insulin usage. Stacey Simms 14:28 I appreciate you going through so granularly, I have learned that my listeners really like the deep dive anytime there is something new. So thanks for walking us through that. And you've mentioned the CGM. Let's talk about this. This is all integrated with the Libra when people use the Libra does it alert? Right back to Jeffrey answering my question but first Diabetes Connections is brought to you by Dario health and one of the things that makes diabetes management difficult for us that really annoys me and Benny isn't actually the big picture stuff. It's all the little tasks adding up. Are you sick of running out of strips? Do you need some direction or encouragement going forward with your diabetes management with visibility into your trends help you on your wellness journey? The Dario diabetes success plan offers all of that and more No more waiting in line at the pharmacy no more searching online for answers. No more wondering about how you're doing with your blood sugar levels, find out more go to my dario.com forward slash diabetes dash connections. Now back to Jeffrey Brewer answering my question about using the abbot libre here, does it alert an alarm? Jeffrey Brewer 15:40 Very good question. So the way the library works is it gives data in two different manners. One is you take the pen cap and you swipe it over the library. And it gives you an on demand reading for what your glucose is at that particular moment. And that's the value that is used in order to calculate any corrections. But there's another way that libri is communicating, which is directly through Bluetooth to the smartphone. Because we have an app on the smartphone. And that's monitoring. For instance, for hypoglycemia, you have a couple different ways the library is working in order to support a person with diabetes, it's either directly on demand to make the calculation on the pen cap or go into the phone for monitoring for hyperglycemia. These are particular capabilities of the library to Stacey Simms 16:27 his delivery that is in big for Unity. Are there any different features? Or is it the same one that people can buy separately? Jeffrey Brewer 16:34 Well, it's the same libri puck. So the sensor itself, the part that you wear on your body, it's the exact same one that gets prescribed and fulfilled at the pharmacy or wherever else a person gets their lead rays. The difference is that we're not using the reader that avid makes, or the app that avid will have on the phone, the libri in our context is talking directly to our pen caps and to the app on the phone. So it's fully integrated into the system. This is an amazing thing that avid has given us, which is the ability to make it very, very simple for the end user such that you don't have to apps you have to worry about all the training is comprehensively designed such that I learned to use the library and the context Bigfoot system, one training one app, one company that's gonna support the whole system, Bigfoot, and then all the data that gets captured, whether we're talking about insulin data or glucose data, and then made available to clinicians in a unified interface to support them in adjusting the therapy over time. Stacey Simms 17:38 Well, this may be a really dumb question. I know that the Libra you scan with the phone, when it's separate from Bigfoot in Bigfoot Unity, do you scan with the pen? Or is it just automatic, Jeffrey Brewer 17:48 it's with the pen, you scan. That's actually the only way you can get right now what's my glucose reading from the CGM is through that NFC interface on the library puck. And one of the key design elements that we felt very strongly about is that you don't have to open up an app on a phone, in order to give yourself a shot. Literally, you're just carrying that pen which you would have with you for meals during the day, it already has the pen cap on it. So you don't carry another device and you're wearing the Libra on the back of your arm, all you have to do is wear the Libra Ray, and then scan that Libra with the pen cap, then it tells you what to do. And no opening an app on the phone, no unlocking the phone, selecting an app opening and navigating through pages, that adds too many steps. And it's frankly, peep something people don't want to do. So we tried to make it as close to what they're doing today, which is you've already got a pen that you're carrying around, we're not adding another device, you don't have to add any additional steps, all you got to do is wear the LIBOR rate and we take that data and then make advice as to what to do. Stacey Simms 18:54 You know, one of the issues with pens is that they'll switch you insulin brands. So you know the insurance when your will cover human log the next year it wants you to take novolog and the pens aren't the pens different the caps fit and the different pens geoffry. Jeffrey Brewer 19:08 The pens are different between the different manufacturers. And then some cases from the same manufacturer, you have different designs, different diameters and geometries and clearance for the needles. What we've done is besides designing different pen caps for all the different insulins, we have basically supported this as a service offering. So when you're using Bigfoot, if you didn't buy a pen cap, you are a customer for the entire offering. And if you get switched by your insurance company from humulus, novolog or back, we're just going to send you the new pen cap that fits the insulin that you're currently prescribed, which is we think one of the big challenges that people have and we've heard and we wanted to make sure that that was an easy transition for people. Stacey Simms 19:54 That's great. And you've already mentioned the way it's packaged, but I'd like to just talk about that. Little bit more I remember. And it was either when we first talked in 2015, or you know, some point very early on that you all were adamant that this was not going to be piecemeal. And you were also going to make it easier for people to purchase things all together. So this is, this is a terrible way to describe it every in my head, I sort of think of those boxes, the subscription boxes, people get right with my kids, it was like, you'd get little fun comic book stuff in them, right, or you'd get a subscription box of exciting bath luxury items. This is obviously not that this is a box with everything in it, right, everything comes together. Jeffrey Brewer 20:34 That's right, when you first initiate therapy, you don't have to go and get a prescription filled, really braise a prescription field for a blood glucose monitor for test strips for lancets. For pen needles, basically, it's all there in the box. And it's trained and set up in a unified fashion. That frankly, just makes it easier to learn. And it makes it more convenient. And we thought that's an important part of the customer experience. There's a lot of blaming, that takes place of the patient in the world that says, Well, people just aren't working hard enough. They're not doing the things that their clinician told them to do. If they were everything would be better, and diabetes wouldn't be a problem. And frankly, we just don't agree with that. We think that it's too complicated, it's too hard. And that it should be easier. So one of the things that needs to be easier is all the different supplies and getting those and making sure you have the right supply. Having access to the tools is something that needs to take place in order for you to be able to successfully use the therapy, we figure if we make that easier if we make it easier to remember things or you don't even have to remember things because we remind you or we descend them to you without you having to remember all that kind of stuff, I think really adds up to a better experience easier and more convenient use of the system, we firmly believe it's going to end up in better results. Because it's just people are going to do things that are more convenient and easier for them to do. So we make it as easy as possible. Stacey Simms 22:03 any issues getting insurance and Medicare coverage when it's all bundled like this. I mean, I'm asking is did Bigfoot have any issues getting it? And is it covered for people now? Jeffrey Brewer 22:13 Why Yeah, there's a lot of innovation that we're having to undertake in order to be able to deliver this to people. One of the aspects of innovation is that we're working through clinics, or endocrinology practices. And this is how we deliver the solution, the clinician will prescribe and then bill for not only the system, but the services of the clinician to use the system and support the system for the person with diabetes. And then when bill comes in, it comes from the clinician. So in order to make this simple, so that there aren't all these different prescriptions. And there aren't all these different places where you have to get all the different pieces, we're working through the clinician. And in this case, there are already codes that are available called remote physiologic monitoring codes that support the treatment of chronic disease and tools in order to support better treatment in chronic disease. And so we're providing these tools to the clinician, and then the clinician basically delivers them through to the patient. And the billing relationship is between the patient and the clinician. All of it gets simplified and makes everybody's life easier. What we're doing is covered by Medicare and private payers more broadly, because we didn't go and get a code for Bigfoot, what we did get is a plan to go and use codes that are already there that clinicians can access in order to reimburse both for what we're providing, and for the services that they have in order to support the effective usage of the system Stacey Simms 23:46 looking forward, because of course, we can never just let something come out, we always have to see what's next. You know, we talked a lot about interoperability is Unity, going to integrate with different cgms or different systems down the road is that in the plans, Jeffrey Brewer 24:00 not in the immediate plan, what we did is we said, we're going to pick what we think is the best CGM for what we're trying to do, which is simple, easy, cost effective and very scalable across a large population. And the library has some very unique capabilities that that we feel very much support what we're trying to accomplish. And so we did a deep partnership with avid, as I said, they've given us the ability to integrate their sensor into our system in a way that other systems are not integrated closed loop systems. Today, you have a company that sells you a sensor, you have a company that sells you a pump, they have different apps on the phone that are going to govern, you know their respective products, they're going to be uploaded to clouds that sometimes require clinicians to look into different places to see the full picture for data. We're doing something much simpler. Describe what we're doing is more like what Apple does. Apple takes a bunch of different pieces, some of which they licensed and some of which they may integrates them into the most usable package that actually is going to be accessible to the most people. That's the way we think about it as well. There are other sensors out there and great options for other sensors. We're not trying to say you have to switch to us if you're happy with your other solution. We're trying to go after a population of people who literally don't have any solutions today and are feeling pretty ill served. We think that with all the people out there that are still to use CGM are still to benefit from CGM and the kind of tools we put around CGM. We don't see ourselves as competing with others. We're just trying to get the goodness that we believe we've created out to people who who need it, Stacey Simms 25:39 I got a question from a listener I meant to ask we were talking about scanning depends. And that was, if a person can still use the the libri, to reader and the librelink app to scan the sensor. Or once you do this, if it is only linked with Bigfoot system? Jeffrey Brewer 25:53 Well, in order to get the benefit of the system, you need to use the pen caps, because that's where the data is captured. That's where the recommendations get made. And it works best in the context of the Bigfoot system. Stacey Simms 26:05 So you can't you can't link it to two different things. In other words, you couldn't use the reader and the pen. Jeffrey Brewer 26:10 Not at the same time, you could use the library separately with a library reader and a librelink. app, but not at the same time. Stacey Simms 26:20 I'd love to get an update Jeffrey, if you could on what I believe is called Bigfoot autonomy, which was the pump system that we did first talk about all those years ago? Can I ask you what the plan is for that, or what you could share with us about it, it is called Bigfoot autonomy, right? Jeffrey Brewer 26:35 That is the name that we have picked for it. Yes, autonomy and Unity Unity use for the shots and autonomy is for the pumps, we have, as you know, a pump ourselves, we have developed and done clinical work for algorithms that we have utilized for closed loop insulin delivery. And we've also developed the full package around how to deliver it as a single thing, using a libri. In a very parallel fashion to what we've done with a foot Unity, we had to focus on one product in order to launch the company and to establish ourselves. So we picked this path because we think it gives us the opportUnity to reach the most people most quickly that frankly, don't have other options available to them. And we think we're going to be able to establish a reputation in the marketplace. In the future Bigfoot autonomy is going to complement Bigfoot Unity and present another option for how people can have insulin therapy. That is something we're committed to down the road. Stacey Simms 27:34 So the people that were very enthusiastic, there's this this whole commUnity that was you know, the DIY commUnity and the we are not waiting commUnity, they should not look at Unity and say, well, Bigfoot has stopped with the pump, right? They shouldn't think that this is not going to go forward. It's not still in the plan. Jeffrey Brewer 27:51 Well, the plan is always and will remain that we're offering choice and selection of different opportunities for people that have different needs. Just as Medtronic today, in acquiring the companion in pen now realizes it's not about pumps or pen, it's about both, we've been saying the same thing for quite a while, we're just starting with the pens, and then expanding to the pumps, versus everybody else is now interested in pens and started in pumps, it's really the same thing. It's a different way of serving a particular part of the population that has different needs, pumps are great. And they can deliver a lot of value and a lot of quality of life. However, they're not going to be right for everybody. And there's going to be a lot larger population of people who will still take shots for the foreseeable future, especially globally. And so it's not a matter of either or it's both in our minds, Stacey Simms 28:43 if your son is living with type one for almost 20 years now. And of course, I think most people got familiar with your name when you were at jdrf really pushing the artificial pancreas program. I wonder if you could just take a second to give us some perspective, because I don't know about you. But my son was diagnosed in 2006. And it almost seemed like for the first eight years, maybe even 10 years, there just didn't seem to be that innovation on the commercial side of things. And now, I feel like I know it's it's not there's no cure. I know it's we're not there yet. But I do feel like the technology is finally working hard. You know, we're doing things for my son. And it's not just pump technology, as you said it's pen technology. And I feel like at least he can do a little less work. Jeffrey Brewer 29:25 I feel the same way. There's been a tremendous amount of progress from 2002 when my son was diagnosed in 2012. There wasn't much of any progress. It has been accelerating in recent years. And I give a lot of credit to jdrf and the work that the volunteers supporting jdrf did to advocate to the executive branch to the legislative branch and then directly to the FDA, we were able to establish a very strong platform for collaboration and the way the FDA has prioritized the innovation in diabetes. enabled it with some clear rules of the road. I believe that's what made it all possible. There has been development of technologies that weren't mature before. But if they didn't have a path through to the marketplace, through the FDA process that worked, we wouldn't benefit from all these things. So it has been a journey. And I think it's been, you know, development of technology. It's been developed in the regulatory practices. It's been greater familiarity and openness amongst clinicians, and also the payers who see value and these tools for patients. So a lot of things that had to change, healthcare is much more complicated and difficult to work in than what I previously did in my high tech career. But it's much more rewarding, because I think it's now having a big benefit and a lot of people and we're happy to join the party, as Bigfootbiomedical. Unknown Speaker 30:47 Do you mind if I ask how your son's doing? Jeffrey Brewer 30:48 Yeah, he's actually doing very well with his diabetes, I will tell you that between the ages of like 15 and 22, it was kind of rough. It was a very similar story that I heard from many parents when I was a CEO of jdrf. It's a really challenging condition to live with adolescents and young adults. But he sort of found his way through that, and now has refocused on taking care of himself. And the tools are better now, to enable him to do that. So I think that it's gone hand in hand, his maturation and the development of these tools. And you know, I think he's in a good place. And hopefully, we can make it better over time. You know, it's Stacey Simms 31:27 funny, I'm not quite sure this is gonna come out appropriately. So I'll try to be careful. But it's kind of nice to free in a way to know that even the head of jdrf. And even the guy at Bigfoot has a kid who was a teen, and struggled. And I know that sounds weird. I don't wish anybody to struggle. Like I wish all the kids went through this, and we're fine. And everybody was the poster child. But I appreciate you sharing that. Jeffrey Brewer 31:50 It's important because I don't think that people talk about it enough. How hard it is for families, how hard it is for the kids, and how young adults, their brains are just not meant to cope with a responsibility like this. It's just not right. It's not something that they're ready for. And, you know, so nobody should be surprised that it's very hard. And it certainly journey. I think it'd be better if people understood that from the beginning, you know, because some people yeah, you're right, they think it's just my kid that's having this trouble. But it's not, it's that this is really, really hard for any family. And it frankly, is the rare family, where you have just a completely well adjusted and easygoing kid with type 1 diabetes. That's the rarity, not the norm. We're a company that stems from the patient experience, you know, my knee through my son, obviously, it's not the same thing as having it. But you know, having a child that grew up with it, a lot of people at Bigfoot have insulin requiring diabetes and know what it's like to live with this drug. I think it's given us a really great perspective on some of the softer aspects of the experience have been missed by some of the medical device companies, things about making it easier and less stressful and just more convenient. Because when you got to do something every day, multiple times a day for the rest of your life, it's just a different kind of thing. And even small benefits to simplicity can have a huge impact and adding up to much less burden, emotionally or intellectually. And I think that all adds up to better lives. We can't point to any one thing about Bigfoot Unity and say, this is the thing that really makes the difference. It's really a bunch of different things that are really holistically designed to as a system, the sustainable and usable on a daily basis. And I think that's really the future of chronic disease and, and we're glad to be able to help tell that story. Stacey Simms 33:45 Well, thanks for spending so much time with me. I really appreciate you going through it. And I'm sure we will talk again soon. Jeffrey, thanks so much for being with me. Unknown Speaker 33:57 You're listening to Diabetes Connections with Stacey Simms. Stacey Simms 34:03 Lots more information about Bigfoot. I will link it up in the show notes at Diabetes connections.com. I have been hearing some weird things about Apple podcasts player recently and some of the other apps that feed off of apple. If you're having any trouble getting links, or even listening to the show. Everything you need is a Diabetes connections.com transcripts of every show. And always please get in touch with me I can usually help you find what you need. Because these are pretty information, dense episodes. And if you prefer to read, I want to make sure you get the info. And if the app isn't helping you then we can help you in a moment. Something really amazing about my recent diabetes, parenting meetup, I met some new families and it was really unusual their experience and what they're doing for the rest of us. It's complicated, but I'll tell you in just a minute. First Diabetes Connections is brought to you by Dexcom. And when we first started with Dexcom back in December of 2013, the share and follow ups weren't not an option. They hadn't come out with Technology yet. So trust me when I say using the share and follow apps makes a big difference. I think it's really important to talk to the person you're following or sharing with. Even if you're following your young child, I'm telling you, these are great conversations to have, you know, at what number will you text? How long will you wait to call that sort of thing. That way the whole system give everyone real peace of mind, I'll tell you what I absolutely love about Dexcom share. And that is helping Benny with any blood sugar issues using the data from the whole day and night. And not just one moment, internet connectivity is required to access separate Dexcom follow up to learn more, go to Diabetes connections.com and click on the Dexcom logo. Okay, it was jumping out of my skin last week, because I had my first diabetes parent meetup since COVID. I think the last one might have been January or February of 2020. Many of you know I run a very large Facebook group for parents of children with type one in the Charlotte area, I think we have almost 1000 people now when we were starting to pull from all over the state because I have come to find out it's a pretty unique group. If you have a local group that you run, or you're part of what makes it unique is mine is based on meeting in person, I try to really stress and set up you know nothing official, I'm not with any organization, I just say hey, let's meet for coffee here, I stress the idea of let's get together in person, let's get the kids to meet let's get the parents to meet. And it can be kind of hard because not everybody I have found is as I don't know if enthusiastic is the right way to put it or pushy or not shy, maybe it's just I'm not afraid of rejection. If I set up a coffee and I invite you know, the whole 1000 people group, and five people show up or one person shows up, I'm still really happy. And I've come to find out that not everyone feels that way. So don't be shy. Just put your stuff out there, get people to come and meet up with you. It will change your life. It really helps me 14 years into it, I think more than anybody else who comes to these things. So I set one up, we only had two people come I'm telling you these things are still amazing. But they were both newer diagnosed families. One had a nine year old daughter diagnosed January of 2021, just this past year, and the other had a 16 year old boy who was diagnosed last summer. And it turns out and I knew this before we met we the kids have some mutual friends. And they're both wrestlers. So Benny knew this other kid as well. But what was amazing to me is that both of these families were already enrolled in clinical trials. And they had been presented with this option. So early on. Now we do not live in an area where clinical trials are present. I mean, I've talked about this on the show before it's we've never been able to get in one. We live in Charlotte, North Carolina, most of North Carolina trials and tests and things are in the Raleigh area over by the Research Triangle, or they're in Virginia, at UVA, or Florida. And that's really the closest to us. So that's where these two families both went for separate trials, both at University of Florida health both I believe at trial net, I may have the exact place but both with Dr. Michael Haller, who we've talked to several times before on this show, one of the kids that the 16 year old is in the Teplizumab trial, the other is in the ATG trial. I'm not going to go into detail on both of these, we've actually talked to Dr. Haller about both of them on the show before. So I will link that up in the show notes as well. But I'll tell you what the ATG trials you've just started. So it's a little too early to tell anything. And of course, this is just with one person. So we should be careful about drawing conclusions. But the 16 year old wrestler, holy cow, so he was diagnosed last year, it's almost a year I believe in In fact, when this episode comes out, it might just be a year. And this is a 16 year old kid. So a teenager who uses probably a lot of insulin, right big kid healthy kid. And I want to say the dad told me that his daily basil is four units. And they're struggling using a pump because he gets such low doses of insulin. They're trying to figure out what to do. Now, who knows, because as I said, it's early on, but it seems to be the thinking that the diploma has really helped make this first year of diabetes, very different than what most 15 or 16 year old kids go through in their first year of diabetes. I'm going to talk to the family. I'll probably circle back around with Dr. Haller again. Because I think that their experience and honestly, it has not been an easy experience. This isn't you know, you go down to Florida, you take a pill you come home, it's a very intense, but brief experience, but they do go I believe, every six months. So I'll tell you more about that as we get there. But I really wanted to bring up with how amazing that these newer families are helping in this way. Obviously they want to help their own children, but they also understand that this is helping the greater commUnity. These are opportunities that did not exist. 14 years ago, when Benny was diagnosed that did not exist possibly, you know, 10 years ago, we have to pull him up in front of the FDA right now. This is really interesting to me, and I know it is to us. You're listening if you're listening this far into the show, certainly, but man and I know I also live in a more affluent area people have more access to health care and to doctors who know about this stuff. But Wow, I was surprised so happily, so To hear that and and to see that their entry into the diabetes community was also an entry into studies that will help everybody you know whether this stuff works or not, it all helps. So I really appreciate it. Okay, before I let you go update on events, my next event is not in person, we're still on zoom for a lot of us but getting in person for more, which is so exciting. On June 5, I'll be speaking at Camp Nejeda. They have a great event for adults with type one, I will link this up in the show notes. And in the Diabetes Connections Facebook group, I'm talking about telling your story and advocacy. So this is more about how to get the media to listen when you want to talk and also maybe just about blogging and speaking Yeah, blogging still Sure why not in podcasting, and tik tok and Instagram, but talking about your story, and advocacy. That's what I'm going to be talking about there. If you're listening in the Charlotte area, we are doing another D parent meetup. That's This Week. If you're listening as the episode first goes live, it'll be Thursday evening. So drop me an email or hit me up on social and I'll give you all the details. And of course, every Wednesday, Diabetes Connections in the news, join me 4:30pm Eastern Time live on Facebook for a very brief five, six minute newscast about what's going on in the diabetes world, all types of diabetes, and that's replayed on social through the rest of the week. And the response to that has been great. So I am going to keep doing it. I'm having a lot of fun with it. All right. Thank you as always to my editor John Bukenas from audio editing solutions. Thank you so much for listening. I'm Stacey Simms. I'll see you back here next week. Until then, be kind to yourself. Benny 41:40 Diabetes Connections is a production of Stacey Simms Media. All rights reserved. All wrongs avenged
On this episode of The Bluebloods, we continue our "PAC-12 in 31 Days" theme with the Arizona State Sun Devils. We are joined by Arizona State Insider and Writer for The Athletic; Doug Haller. We breakdown the 2020 season, Jayden Daniels' potential, Herm Edwards, expectations for Arizona State in 2021, and preview the future of Arizona State Football. All this and more right here on The Bluebloods! --- Support this podcast: https://anchor.fm/the-bluebloods/support
Cam Haller is a Music connoisseur who's rise to fame can be attributed to his superb networking skills & music react videos. As a creator of the CUFBOYS & owner of RANSOM Clothing, Cam has successfully branched into multiple industries while maintaining an evident social media presence.Brand Risk Clips Channel: https://www.youtube.com/channel/UCpesjs3qHT8IHdg3_rKPy2gBrand Risk Vlogs: https://www.youtube.com/channel/UCT740TGslTDW3-C0teYTbdwPodcast Socials:https://twitter.com/BrandRiskGGhttps://www.instagram.com/brandriskgg/https://www.tiktok.com/@brandriskFind Cam at his socials:https://www.instagram.com/camhallerhttps://www.instagram.com/cufboyshttps://twitter.com/camhaller❤️WE'RE ON SPOTIFY & APPLE PODCASTS❤️https://open.spotify.com/show/04vtsIZrVvG9EyOvFGCYeZ?si=sIkErUTfRGqMV5AbMqF_1ghttps://podcasts.apple.com/us/podcast/brand-risk-podcast/id1548242427Podcast Hosts:Arab - https://twitter.com/YourFellowArabQuick - https://twitter.com/Edwiin
We were lucky enough to track down one of our upcoming graduates for this week's podcast as Jessica Haller '21 talks about Health Law and her work in the Justice Center here at Albany Law School! More about Commencement: https://www.albanylaw.edu/students/commencement More about the Health Law Society: https://www.albanylaw.edu/students/organizations More about the Justice Center: https://www.albanylaw.edu/centers/the-justice-center
In this week's #DataTalk, we chat with Eric Haller, Executive Vice President and General Manager of Identity, Fraud & DataLabs at Experian, about the race to digital identification. We talk about how Eric’s role has evolved at Experian, what Experian is doing to mitigate fraud and identity theft for consumers, and the meaning of digital identification. Eric also discusses the digital shift every industry is facing amidst the COVID-19 pandemic, the future of digital identification, and recent innovations in deepfake technology.
Guest host Naomi Shihab Nye is joined by Paul Haller on episode 182 of The Quarantine Tapes. Paul is the former abbot of the San Francisco Zen Center. Naomi and Paul talk about how his practice has changed in the past year, with Paul sharing how his community has been affected by this moment.As the vaccination begins to enter our lives, Paul talks about the experience of reconnecting with friends. He expresses his gratitude for how we are able to appreciate those connections in a new way after our time apart. Paul shares stories from this time at home, introducing listeners to the European bee in his backyard and the other realizations that have come out of this deeper connection to physical space. In their fascinating and thoughtful conversation, Naomi and Paul discuss poetry, silence, and the connections they’ve experienced in the past year. Ryushin Paul Haller has lived and practiced at San Francisco Zen Center since the 1970s and held many positions at Tassajara and City Center. He received Dharma Transmission from Sojun Mel Weitsman and has been teaching for over 30 years. He served as Abiding Abbot at City Center from 2003 to 2012, and is currently the Urban Temple Dharma Teacher at City Center. Originally from Belfast, Northern Ireland, he teaches throughout the US and Europe and has led mindfulness programs to assist with depression and recovery. Paul has also taught in prisons and has a long involvement with the Zen Hospice Project. He has been practicing yoga for 30 years.Naomi Shihab Nye is the Young People's Poet Laureate (Poetry Foundation), the Poetry Editor for the New York Times Magazine, on faculty at Texas State University, and author or editor of more than 30 books. She was selected by the National Book Critics Circle to receive the Ivan Sandrof Lifetime Achievement Award, 2020.
There's a shift in consumer interest to a digital-first shopping format and retailers have been rapidly reinventing their business operating models to align with the current environment. Karl Haller, Partner, Consumer Center of Competency (CoC) Leader at IBM joins to go inside this story. See omnystudio.com/listener for privacy information.
This episode will encourage you to come to Jesus with faith like a child! Today on the show you hear from 13 year old Broadway star, Anna Haller. What you should know about Anna is that she starred in the Broadway production of Disney’s Frozen as Young Elsa in 2019 performing around 70 times. Anna shares her Broadway story and what she learned in the process as well as her journey as a follower of Jesus and how the Lord continues to set her free by His grace. This girl may be young, but she has faith that can move mountains. Listen and be encouraged by her pure and unashamed love for the Lord. I have loved getting to witness her faith in our Rise Collective Women online Bible Study community! At the end of the episode I open the Word of God and talk about the passage Matthew 18:1-5. JOIN ME and Anna in Rise Collective Women today! SUBSCRIBE to my weekly email newsletter for show notes and links from the show FOLLOW me on Instagram @lauraleighturner
Fascinating and frustrating: two words that Dr. Haller uses to describe researching how type 1 diabetes evolves within the human endocrine system. Type 1 diabetes stands at the top of pediatric endocrinology diseases, and Dr. Haller tells listeners about exciting developments in delaying, modifying, and preventing type 1 progression. Listen and learn What evidence in endocrinology and diabetes research shows type 1 as essentially a heterogeneous disease, What trends and differences appear in adult versus juvenile onset of type 1 diabetes, and Which endocrinology diabetes therapies are in the works, including the first ever FDA-labeled drug capable of "changing the natural history of type 1 diabetes." Michael J. Haller, MD, is a professor and Chief of Pediatric Endocrinology at the University of Florida. He specializes in type 1 diabetes mellitus research and clinical work. What causes type 1? Well, that's part of the challenge. Triggers range from genetic to environmental to some mix of both, and Dr. Haller's research grapples with these complex pathways to disease onset. Because it has so many potential combinations of causes, using general approaches and treatments for everyone who is at risk for or has type 1 just doesn't cut it. Various treatments through immunotherapy is his current passion, and he tells listeners of its tremendous potential. For example, he and his colleagues have been looking at drugs that are already out in the market used to treat other diseases like lupus, seeing if they can be applied to affecting the metamorphosis of type 1. Immunotherapy offers a wide spectrum, from suppression to more immune-modulatory effects. In fact, his lab has developed the first drug to delay and prevent type 1 in high risk patients—and it's on course to be the first therapy to get an FDA label for changing the progression of type 1 diabetes. Meanwhile, research continues into how causes come into play, and he describes various approaches, from examining pancreases through a type 1 organ donation program to imaging pancreases in living patients. There's a lot to parse in this research and the work has only just begun, but so far the size of the pancreas seems to be a significant factor: they are still working on determining if that's an outcome or cause, but pancreases that come from type 1 patients tend to be about 50% smaller than average. They're also looking at the exocrine region to see if it has a role. Listen in for exciting ways researchers are making progress in treating this complex disease. For more about these projects, see diabetes.ufl.edu. Available on Apple Podcasts: apple.co/2Os0myK